Reports

Qualcomm's Q4 2024 revenues reached $10.244 billion, a 19% increase year-over-year. GAAP EPS grew by 96% to $2.59, while non-GAAP EPS increased by 33% to $2.69. The company is focusing on growth and diversification initiatives, with strong performance in automotive and IoT sectors.

• Qualcomm's Q4 revenues increased by 19% year-over-year, reaching $10.244 billion.
• GAAP EPS grew by 96% to $2.59, and Non-GAAP EPS increased by 33% to $2.69.

Gilead Sciences announced strong third quarter 2024 financial results, with a 7% increase in total revenue to $7.5 billion. The company is increasing its full-year revenue, operating income, and earnings per share guidance.

• Total revenue increased 7% year-over-year to $7.5 billion.
• Biktarvy sales increased 13% year-over-year to $3.5 billion.

MercadoLibre reported strong Q3 2024 results with net revenues of $5.3 billion, up 35% year-over-year. The company saw solid growth in unique buyers, Fintech MAU, GMV, and acquiring TPV across major geographies. Net income reached $397 million, with a 7.5% margin.

• Net revenues reached $5.3 billion, a 35% increase year-over-year.
• Income from operations was $557 million, representing a 10.5% margin.

McKesson Corporation announced strong second-quarter results, with a 21% increase in consolidated revenues to $93.7 billion and a 13% increase in Adjusted Earnings per Diluted Share to $7.07. The company also raised its full-year adjusted EPS guidance to $32.40 to $33.00.

• Consolidated revenues increased by 21% to $93.7 billion.
• Adjusted Earnings per Diluted Share grew by 13% to $7.07.

CVS Health's total revenues for the third quarter increased by 6.3% to $95.4 billion. GAAP diluted EPS was $0.07, and adjusted EPS was $1.09. The results were impacted by charges related to premium deficiency reserves in the Health Care Benefits segment.

• Total revenues increased by 6.3% compared to the prior year, reaching $95.4 billion.
• GAAP diluted EPS was $0.07, and adjusted EPS was $1.09.

Williams reported a strong third quarter with record Adjusted EBITDA of $1.703 billion, up 3% year-over-year. The company increased its full-year 2024 Adjusted EBITDA guidance midpoint by $125 million to $7.075 billion, reflecting confidence in its core business and project execution.

• GAAP net income increased by 8% to $705 million, or $0.58 per diluted share.
• Adjusted EBITDA reached a record $1.703 billion, a 3% increase compared to Q3 2023.

Sempra reported GAAP earnings of $638 million, or $1.00 per diluted share, for the third quarter of 2024, compared to $721 million, or $1.14 per diluted share, for the same period in 2023. Adjusted earnings for the third quarter of 2024 were $566 million, or $0.89 per diluted share, compared to $685 million, or $1.08 per diluted share in third-quarter 2023.

• Sempra reported third-quarter 2024 GAAP earnings of $638 million, or $1.00 per diluted share.
• Adjusted third-quarter 2024 earnings were $566 million, or $0.89 per diluted share.

Johnson Controls reported a 7% increase in Q4 sales, reaching $7.4 billion, with organic sales growing by 10%. GAAP EPS was $0.95, while adjusted EPS was $1.28. The company's backlog reached a record level, positioning it well for continued profitable growth in fiscal 2025.

• Q4 sales increased 7%, with organic sales up 10%.
• GAAP EPS for Q4 was $0.95; adjusted EPS was $1.28.

Howmet Aerospace reported strong Q3 2024 results with revenue up 11% year-over-year to $1.84 billion and net income of $332 million. The company saw significant growth in the commercial aerospace market, which drove adjusted EBITDA up 27% year-over-year. They also reduced debt and repurchased common stock.

• Revenue increased by 11% year-over-year, primarily driven by growth in the commercial aerospace market.
• Net income was reported at $332 million, or $0.81 per share, compared to $188 million, or $0.45 per share, in Q3 2023.

Cencora's fiscal 2024 fourth quarter saw a significant revenue increase of 14.7% to $79.1 billion. GAAP diluted EPS was $0.02, while adjusted diluted EPS rose by 16.8% to $3.34. The company also announced an 8% increase in its quarterly dividend.

• Revenue increased by 14.7% to $79.1 billion in the fourth quarter.
• GAAP diluted EPS was $0.02 for the quarter.

FICO's Q4 2024 earnings showed significant growth, with revenue increasing to $453.8 million from $389.7 million in the prior year. GAAP EPS rose to $5.44, and non-GAAP EPS reached $6.54. The company's performance was driven by strong growth in scores revenue and increased recurring software revenue.

• FICO reported Q4 2024 revenue of $453.8 million, a 16% increase year-over-year.
• GAAP EPS for Q4 2024 was $5.44, compared to $4.01 in the prior year period.

Corteva's third quarter results were impacted by reduced planted area and market dynamics in Latin America, as well as competitive pricing environment in Crop Protection. Net sales decreased by 10% and the company reported a GAAP loss of $519 million. Crop Protection volume increased due to demand in Latin America and North America, while Seed volume declined due to reduced corn planted area in Argentina. The company updated its full-year 2024 guidance.

• Net sales decreased by 10% compared to the same period last year.
• GAAP income from continuing operations after income taxes was a loss of $519 million.

HubSpot reported a strong Q3 2024 with total revenue of $669.7 million, a 20% increase year-over-year. GAAP net income was $8.1 million, or $0.16 per share, compared to a net loss in Q3 2023. The company grew its customer base to 238,128 and generated $129.2 million in non-GAAP free cash flow.

• Total revenue increased by 20% year-over-year, reaching $669.7 million.
• GAAP net income was $8.1 million, a significant improvement from the net loss in Q3 2023.

Take-Two Interactive Software, Inc. reported its results for the second quarter of fiscal year 2025. Net Bookings were $1.47 billion, at the top of the guidance range, driven by the success of the Grand Theft Auto and Borderlands franchises. The company is reiterating its fiscal year 2025 Net Bookings guidance range of $5.55 to $5.65 billion.

• Total Net Bookings grew 2% to $1.47 billion compared to $1.44 billion last year.
• Net Bookings from recurrent consumer spending grew 6% and accounted for 81% of total Net Bookings.

Iron Mountain reported a strong third quarter with record revenue, adjusted EBITDA, and AFFO. Total revenue increased by 12.2% to $1.6 billion, driven by growth in both storage rental and service revenue. Adjusted EBITDA rose by 13.6% to $568.1 million, and AFFO increased by 10.2% to $332.0 million.

• Total revenue for the third quarter increased by 12.2% to $1.6 billion.
• Net income for the third quarter was $(33.7) million.

ANSYS reported a strong third quarter in 2024, with a 31% increase in revenue to $601.9 million and a GAAP diluted EPS of $1.46. The company's ACV grew by 18%, and they closed an $88 million contract in the high-tech industry. However, due to the pending acquisition by Synopsys, Ansys has suspended quarterly earnings conference calls and no longer provides quarterly or annual guidance.

• Revenue reached $601.9 million, a 31% increase year-over-year.
• GAAP diluted earnings per share were reported at $1.46, while non-GAAP diluted earnings per share were $2.58.

Texas Pacific Land Corporation announced strong Q3 2024 results, highlighted by strategic acquisitions in the Delaware and Midland Basins, record royalty production, and a 37% increase in the regular dividend. The company reported a net income of $106.6 million and adjusted EBITDA of $144.1 million.

• Acquired mineral interests across approximately 4,106 net royalty acres in the northern Delaware Basin for $120.3 million.
• Acquired approximately 4,120 surface acres in the Midland Basin for $45.0 million.

Ameren Corporation reported a GAAP diluted EPS of $1.70 for Q3 2024, compared to $1.87 in Q3 2023. Adjusted non-GAAP diluted EPS was $1.87, consistent with the previous year. The company reaffirmed its 2024 adjusted EPS guidance range of $4.55 to $4.69 and introduced 2025 EPS guidance of $4.85 to $5.05.

• Third Quarter GAAP Diluted Earnings Per Share (EPS) were $1.70 in 2024 vs. $1.87 in 2023.
• Third Quarter Adjusted (Non-GAAP) Diluted Earnings Per Share were $1.87 in 2024 vs. $1.87 in 2023.

Franco-Nevada reported $275.7 million in revenue for Q3 2024, an 11% decrease compared to Q3 2023 but a 14% increase when excluding the impact of Cobre Panama. Net income was $152.7 million, or $0.79 per share, while Adjusted EBITDA reached $236.2 million. The company maintained a strong financial position with no debt and $2.3 billion in available capital.

• Record gold prices generated higher revenues, Adjusted EBITDA and earnings in Q3 compared to Q2 2024.
• Initial contributions from the newly commissioned Tocantinzinho mine in Brazil and increased contributions from Greenstone mine and Yanacocha royalty.

Teva Pharmaceutical Industries Ltd. reported a strong third quarter of 2024, marking the seventh consecutive quarter of growth with global revenues reaching $4.3 billion, a 15% increase in local currency terms compared to the third quarter of 2023. The company's innovative portfolio and generics business drove this performance, leading to an increased 2024 financial outlook, including revenues, Adjusted EBITDA, and Non-GAAP EPS.

• Global revenues reached $4.3 billion, a 15% increase in local currency terms compared to Q3 2023.
• Innovative portfolio and generics business drove strong performance.

PTC announced its Q4 and full fiscal year 2024 results, highlighting solid ARR and cash flow growth. The company's ARR grew by 14% as reported and 12% on a constant currency basis. Revenue increased by 15% year-over-year, with significant growth in operating cash flow and free cash flow.

• ARR grew 14% year-over-year as reported and 12% on a constant currency basis.
• Revenue increased 15% year-over-year, driven by recurring revenue.

Atmos Energy Corporation reported its Q4 fiscal 2024 results, with full-year earnings per diluted share of $6.83 on net income of $1 billion. The company also initiated fiscal 2025 earnings per diluted share guidance to be in the range of $7.05 - $7.25.

• Atmos Energy reported earnings for the fourth fiscal quarter and year ended September 30, 2024.
• Fiscal year earnings per diluted share were $6.83 on net income of $1 billion.

STERIS reported a 7% increase in total revenue from continuing operations, reaching $1.3 billion. The company reiterated its full year outlook for fiscal 2025, with adjusted EPS increasing to $2.14.

• Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%.
• As reported EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14.

Zillow Group reported a strong third quarter with total revenue of $581 million, a 17% increase year-over-year. The company exceeded its revenue and Adjusted EBITDA outlook, driven by growth in residential, rentals, and mortgages revenue. Net loss was $20 million, while Adjusted EBITDA reached $127 million.

• Zillow Group's Q3 revenue grew 17% year-over-year, exceeding the company's outlook.
• Residential revenue increased by 12% year-over-year, driven by improved conversion rates.

Trimble announced strong Q3 2024 results, with revenue at $875.8 million and a record ARR of $2.19 billion. The company's gross margin also reached a record high. Despite a year-over-year revenue decrease, organic revenue increased by 3 percent. Trimble is raising its full year guidance.

• Record annualized recurring revenue, reflecting ongoing execution of the Connect & Scale strategy.
• Record gross margin, demonstrating continued business transformation and favorable mix shift.

Sun Communities reported a net income of $288.7 million, or $2.31 per diluted share, for the quarter ended September 30, 2024, compared to $120.1 million, or $0.97 per diluted share, for the same period in 2023. Core FFO was $2.34 per share, as compared to $2.57 for the same period in 2023. North America Same Property NOI increased by 0.5%.

• Net income per diluted share was $2.31 for the quarter.
• Core FFO per share was $2.34 for the quarter.

Owens Corning reported strong third-quarter 2024 results, with net sales of $3.0 billion, a 23% increase from the prior year, driven by the newly acquired Doors business. The company's net earnings were $321 million, with an adjusted EBIT of $582 million. They delivered diluted EPS of $3.65 and adjusted diluted EPS of $4.38. The company generated strong operating cash flow and returned $252 million to shareholders through dividends and share repurchases.

• Net sales reached $3.0 billion, a 23% increase year-over-year, with the Doors business contributing $573 million.
• Net earnings margin was 11%, adjusted EBIT margin was 19%, and adjusted EBITDA margin was 25%.

Fidelity National Financial, Inc. (FNF) reported net earnings attributable to common shareholders for the third quarter of $266 million, or $0.97 per diluted share, compared to $426 million, or $1.57 per share, for the third quarter of 2023. Adjusted net earnings attributable to common shareholders for the third quarter were $356 million, or $1.30 per share, compared to $333 million, or $1.23 per share, for the third quarter of 2023.

• Title Segment revenue increased by 12% to $2.1 billion.
• Adjusted pre-tax title margin was 15.9%.

Duolingo reported a strong third quarter in 2024, with significant increases in daily active users (DAUs), paid subscribers, and total revenue. Total revenues increased by 40% year-over-year, and the company saw a substantial rise in net income.

• Total bookings increased by 38% year-over-year, reaching $211.5 million.
• Subscription bookings grew by 45% year-over-year, totaling $176.3 million.

Royalty Pharma reported a strong third quarter with a 15% increase in Portfolio Receipts to $735 million. The company also increased its capital deployment to $1.2 billion and raised its full-year guidance for Portfolio Receipts to $2.75 to $2.8 billion.

• Portfolio Receipts grew by 15% to $735 million.
• Royalty Receipts increased by 15%, driven by Trelegy, Evrysdi, the cystic fibrosis franchise, and Tremfya.

Performance Food Group Company had a strong start to fiscal 2025, with solid sales momentum and adjusted EBITDA growth. The core business performed exceptionally well, and the integration of recent acquisitions of Cheney Brothers and José Santiago into the Foodservice business is expected to drive significant profit growth and increase market share opportunity.

• Total case volume increased 2.6%.
• Total Independent Foodservice case volume increased 7.8%.

RenaissanceRe reported a net income of $1.2 billion and an operating income of $540.3 million for Q3 2024. The company's annualized return on average common equity was 47.1%, and the combined ratio was 84.8%. Large loss events had a net negative impact of $243.2 million.

• Net income available to common shareholders was $1.2 billion.
• Operating income available to common shareholders reached $540.3 million.

JLL reported a strong third quarter with double-digit revenue growth and improved profitability, driven by high demand for outsourcing services and increased transactional activity. Revenue reached $5.9 billion, up 15% in local currency, with significant growth in Leasing, Capital Markets, and Work Dynamics.

• Revenue increased by 15% in local currency, reaching $5.9 billion.
• Diluted earnings per share increased to $3.20, compared to $1.23 in the prior year.

U-Haul Holding Company reported net earnings available to common shareholders of $186.8 million for Q2 2025, a decrease compared to $273.5 million for the same period last year. EPS for Non-Voting Shares were $0.96, down from $1.40 in the previous year. Self-storage revenues increased by 7.5%, while self-moving equipment rental revenues saw a modest increase of 1.7%.

• Net earnings decreased to $186.8 million compared to $273.5 million in the same quarter last year.
• Earnings per share for Non-Voting Shares (UHAL.B) declined to $0.96 from $1.40 year-over-year.

Coherent Corp. reported its Q1 fiscal year 2025 results, with revenue of $1.35 billion, a 28% increase year-over-year. GAAP EPS was reported at ($0.04), improved by 94% year-over-year, and non-GAAP EPS was $0.74, a 357% increase year-over-year. The company also paid down $118 million of its outstanding debt.

• Q1 revenue reached $1.35 billion, reflecting a 28% increase year-over-year.
• GAAP gross margin was 34.1%, a 499 bps increase year-over-year; non-GAAP gross margin was 37.7%, a 293 bps increase year-over-year.

Host Hotels & Resorts, Inc. reported results for the third quarter of 2024, with a comparable hotel Total RevPAR growth of 3.1%. The company maintained its previous full-year comparable hotel guidance at the midpoint despite the impact of hurricanes in Florida. During the quarter, the company repurchased $57 million of common stock and completed the issuance of $700 million of Series L senior notes.

• Comparable hotel Total RevPAR was $328.86 for the third quarter of 2024, representing an increase of 3.1% compared to the same period in 2023, due primarily to improvements in food & beverage revenues driven by group business.
• Comparable hotel RevPAR was $206.21 for the third quarter of 2024, representing an increase of 0.8%, compared to the same period in 2023 and reflecting continued strong group demand, along with moderating domestic leisure demand and the slow, yet improving, recovery in Maui.

Klaviyo reported strong third quarter results with revenue growth of 34% year-over-year, driven by expansion in new customers, mid-market growth, existing customer expansion, and international growth. Revenue reached $235.1 million, with operating cash flow at $38.8 million and free cash flow at $34.2 million.

• Launched Klaviyo in five new languages and now support seven languages on the platform.
• Expanded SMS offering to 18 countries with availability in Norway, Denmark, Sweden, Finland, Italy, and Portugal.

Permian Resources announced strong Q3 2024 results, with average daily crude oil production of 160,801 Bbls/d and total production of 347,091 Boe/d. The company reduced D&C costs to approximately $800 per lateral foot and increased its full-year production guidance. They generated $954 million in net cash from operating activities and $303 million in adjusted free cash flow.

• Crude oil production averaged 160,801 Bbls/d and total production averaged 347,091 Boe/d.
• D&C costs reduced to ~$800 per lateral foot, a 16% decrease from 2023.

Albemarle Corporation reported third-quarter 2024 net sales of $1.4 billion, a 41% year-over-year decline. The company experienced a net loss of ($1.1) billion, or ($9.45) per diluted share, including pre-tax charges of $861 million. Adjusted EBITDA was $211 million, with Specialties and Ketjen showing significant year-over-year growth.

• Net sales were $1.4 billion, with Energy Storage and Specialties volumes up 16% and 4%, respectively.
• Net loss was ($1.1) billion, or ($9.45) per diluted share, including pre-tax charges of $861 million.

Pinnacle West reported a slight decrease in net income for Q3 2024 compared to the previous year, primarily due to increased expenses. However, record-setting summer heat drove increased customer sales and usage, contributing to strong financial results.

• Experienced record-setting summer heat that drove an increase in customer sales and usage.
• Operating performance and reliability remained strong for customers.

Primerica reported strong third-quarter results, with an 11% increase in total revenues to $774.1 million and a 31% increase in net earnings per diluted share to $5.72. The company benefited from sustained recruiting momentum, growth in new life-licensed representatives, and favorable equity market conditions.

• Life-licensed sales force grew by 7%, driven by solid recruiting and a 17% increase in new life licenses.
• Investment and Savings Products sales increased by 34% to $2.9 billion.

Fortune Brands Innovations reported Q3 2024 sales of $1.2 billion, an 8% decrease compared to Q3 2023. EPS increased by 2% to $1.09, while EPS before charges/gains decreased by 3% to $1.16. The company updated its full-year 2024 guidance to reflect current market conditions and the impact of recent hurricanes.

• Q3 2024 sales were $1.2 billion, down 8% versus Q3 2023; organic sales excluding the impact of China were down 5%.
• Q3 2024 earnings per share (EPS) were $1.09, an increase of 2% versus a year ago.

Royal Gold reported a record revenue of $193.8 million and net income of $96.2 million, or $1.46 per share, for the quarter ended September 30, 2024. The company also saw new revenue contributions from the Manh Choh and Côté Gold mines and completely repaid its outstanding borrowings on its credit facility.

• Record revenue of $193.8 million, a 40% increase over the prior year period
• Operating cash flow of $136.7 million and earnings of $96.2 million; 39% and 95% increases, respectively, over the prior year period

Vertex reported strong Q3 2024 results with revenue above guidance, mid-teens organic growth, GAAP profitability, and significant cash flow. The acquisition of ecosio was completed, expanding the company's global cloud platform for e-invoicing and VAT compliance.

• Total revenues reached $170.4 million, reflecting a 17.5% year-over-year increase.
• Software subscription revenues grew to $146.3 million, a 20.6% increase year-over-year.

Kyndryl reported revenues of $3.8 billion, a net loss of $43 million, and record total signings of $5.6 billion, which is a 132% increase year-over-year. The company reaffirms its outlook for fiscal year 2025, expecting constant-currency revenue growth in the fourth quarter.

• Revenues for the quarter totaled $3.8 billion with a net loss of $43 million.
• Adjusted EBITDA was $557 million, adjusted pretax income was $45 million, and adjusted net income was $3 million.

Match Group's Q3 2024 saw a 2% increase in total revenue year-over-year to $895 million, with adjusted operating income rising by 3% to $343 million. Tinder's payer trends improved, while Hinge experienced substantial revenue growth. The company is focused on innovation, efficiency, and managing its diverse brand portfolio.

• Total Revenue increased by 2% year-over-year to $895 million, or 3% on an FX neutral basis.
• Adjusted Operating Income grew by 3% year-over-year to $343 million, with a 38% margin.

APA Corporation reported a net loss of $223 million, or $0.60 per diluted share, primarily due to non-cash impairments. However, adjusted earnings were $370 million, or $1.00 per diluted share. The company's adjusted EBITDAX was $1.6 billion. APA also announced the final investment decision for a major oil development project in Suriname and streamlined its Permian footprint.

• Reported production of 467,000 BOE per day; adjusted production, excluding Egypt noncontrolling interest and tax barrels, was 395,000 BOE per day.
• Announced final investment decision (FID) on 220,000 barrels per day oil development project in Suriname.

MarketAxess reported a 20% increase in total revenues to $206.7 million for Q3 2024, driven by strong growth in total credit average daily volume (ADV) and record portfolio trading ADV. The company's diluted earnings per share increased by 30% to $1.90, and net income rose to $71.5 million.

• Total revenues increased by 20% to $206.7 million.
• Diluted earnings per share increased by 30% to $1.90.

Charles River Laboratories reported a revenue of $1.01 billion for Q3 2024, a 1.6% decrease compared to Q3 2023. GAAP EPS was $1.33, while non-GAAP EPS was $2.59. The company is navigating a challenging period with biopharmaceutical clients reducing spending, but biotech funding has improved, showing early signs of stabilization.

• Third-quarter revenue was $1.01 billion, a 1.6% decrease year-over-year.
• GAAP earnings per share were $1.33, and non-GAAP earnings per share were $2.59.

Sunoco LP reported a net income of $2 million for Q3 2024, a significant decrease compared to the $272 million in Q3 2023. Adjusted EBITDA for the same period was $456 million, up from $257 million in the previous year. Distributable Cash Flow, as adjusted, reached $349 million, compared to $181 million in Q3 2023. The Fuel Distribution segment saw an increase in Adjusted EBITDA to $253 million, with fuel sales volumes increasing by 1% to approximately 2.1 billion gallons. The Board of Directors declared a distribution of $0.8756 per unit for Q3 2024.

• Net income for Q3 2024 was $2 million, a decrease from $272 million in Q3 2023.
• Adjusted EBITDA for Q3 2024 was $456 million, compared to $257 million in Q3 2023.

Blue Owl Capital Corporation announced its Q3 2024 financial results, reporting a net investment income per share of $0.47, and a net asset value per share of $15.28. The company saw new investment commitments of $1.2 billion and maintained a strong portfolio.

• Net investment income per share was $0.47, exceeding the regular dividend by 27%.
• A third quarter supplemental dividend of $0.05 per share was declared.

Jazz Pharmaceuticals announced strong Q3 2024 results with record revenues exceeding $1.05 billion. Key growth drivers, including Xywav, Epidiolex, and Rylaze, saw a combined 14% year-over-year revenue increase. The company has affirmed its 2024 total revenue guidance between $4.0 to $4.1 billion.

• Key growth drivers grew 14% combined year-over-year.
• Zepzelca and atezolizumab combination showed statistically significant and clinically meaningful improvement in OS and PFS primary endpoints.

Revolution Medicines reported its Q3 2024 financial results, highlighting the progress of its clinical-stage RAS(ON) inhibitors, including RMC-6236 and RMC-9805, and the initiation of a Phase 3 pivotal trial for RMC-6236 in metastatic pancreatic cancer. The company's cash position remains strong, enabling operations into 2027.

• Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
• First clinical results for RMC-9805 demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation.

MKS Instruments reported strong third quarter results with revenue of $896 million, GAAP net income of $62 million, and Adjusted EBITDA of $232 million, exceeding the high-end of guidance.

• Quarterly revenue of $896 million, at the high end of guidance
• Quarterly GAAP net income of $62 million and net income per share of $0.92

Chord Energy Corporation reported strong third quarter 2024 financial and operating results. Oil volumes were near the high end of guidance, and capital expenditures were below the low end of guidance. The company repurchased $146MM of shares and issued a three-year outlook (2025-2027) to hold oil volumes flat with $1.4B annual capital spending.

• Cash Flow from Operations and Adjusted Free Cash Flow exceeded expectations in 3Q24, supported by oil volumes near the high-end of guidance and capital below the low-end of guidance.
• Lowering FY24 capital guidance, while raising FY24 oil volumes guidance.

Jackson Financial Inc. reported a net loss attributable to common shareholders of $(480) million, or $(6.37) per diluted share, compared to a net income of $2.8 billion, or $33.35 per diluted share in the third quarter of 2023. However, adjusted operating earnings were $350 million, or $4.60 per diluted share, compared to $315 million, or $3.80 per diluted share in the third quarter of 2023. Retail annuity sales increased by 59% year-over-year, driven by growth across all product lines.

• Retail annuity sales increased by 59% compared to the third quarter of 2023, reaching $5.3 billion.
• Variable annuity sales increased by 8% to $2.6 billion.

Lantheus reported a strong Q3 2024 with an 18.4% increase in worldwide revenue to $378.7 million. GAAP EPS was $1.79, while adjusted EPS was $1.70. The company is narrowing its full-year 2024 revenue and EPS guidance towards the higher end of previous estimates.

• Worldwide revenue increased by 18.4% to $378.7 million compared to Q3 2023.
• PYLARIFY sales increased by 20.6% to $259.8 million, driven by increasing volumes at existing accounts.

Dutch Bros Inc. reported a strong third quarter in 2024, with a 28% increase in revenue to $338.2 million. Systemwide same shop sales grew by 2.7%. The company opened 38 new shops and raised its revenue and adjusted EBITDA guidance for the year.

• Total revenues grew by 27.9% to $338.2 million compared to the same period in 2023.
• Systemwide same shop sales increased by 2.7% relative to the same period in 2023.

Hamilton Lane reported a successful second quarter in fiscal year 2025, marked by steady growth in its core business. Total assets under management reached $131.4 billion, a 10% increase year-over-year, and management and advisory fees grew by 10% compared to the prior year period. The company's GAAP EPS was $1.37, with a GAAP net income of $55.0 million.

• Total assets under management reached $131.4 billion, growing by $12.2 billion year-over-year.
• Management and advisory fees for the quarter were $119.8 million, representing a 10% increase year-over-year.

Coty Inc. reported a 2% increase in net revenues, or 4.5% on a LFL basis, driven by strong growth in prestige fragrances and EMEA. The company saw continued gross margin expansion and operating income growth, while investing in its brands. The company reiterates FY25 EBITDA Underpinned by Accelerating Actions to Adapt Coty for Future Success

• Net revenues grew 2% reported and 4.5% LFL, despite a 1% FX headwind and a 1% headwind from the divestiture of the Lacoste license.
• Prestige net revenues increased 5% reported and 7% LFL, driven by fragrances.

Starwood Property Trust reported a net income of $76.1 million and Distributable Earnings of $159.0 million for Q3 2024. They originated or acquired $2.1 billion of assets and raised $800 million in capital, bringing liquidity to a record $1.8 billion.

• GAAP Earnings were $0.23 per share and Distributable Earnings (DE) were $0.48 per diluted share.
• Originated or acquired $2.1 Billion of assets in the quarter.

Clearwater Analytics announced strong Q3 2024 results, with record revenue of $115.8 million, a 22% year-over-year increase. Annualized Recurring Revenue (ARR) reached $456.9 million, up 26% year-over-year. Net income was $4.8 million, and adjusted EBITDA grew by 34% to $38.3 million. The company also highlighted its investments in R&D and new products, as well as an agreement to terminate the Tax Receivable Agreement.

• Clearwater Analytics achieved record quarterly revenue of $115.8 million, representing a 22% year-over-year increase.
• Annualized Recurring Revenue (ARR) grew to $456.9 million, a 26% increase compared to the previous year.

Joby Aviation reported a strong financial foundation with $710 million in cash and short-term investments at the end of the third quarter of 2024. The company also completed its first international demonstration flights in Japan and reached a landmark in its journey to type certification.

• Completed international demonstration flights in Japan.
• Reached a major landmark with the completion of the first FAA-conforming major sub-assembly.

e.l.f. Beauty reported a strong Q2 with a 40% increase in net sales, driven by significant market share gains in the U.S. and international growth. The company's 23rd consecutive quarter of net sales growth and market share gains.

• Net sales increased by 40% to $301.1 million.
• Gross margin increased approximately 40 basis points to 71%.

Guardant Health reported a 34% increase in revenue for Q3 2024, reaching $191.5 million, driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds. The company raised its 2024 annual revenue guidance to $720 to $725 million and improved its free cash flow to $(55) million. Shield received favorable Medicare pricing of $920.

• Revenue increased by 34% to $191.5 million compared to Q3 2023.
• Clinical tests (excluding Shield) increased by 21% and biopharma tests increased by 40% compared to Q3 2023.

Workiva reported a total revenue of $186 million for Q3 2024, representing a 17% year-over-year growth. Subscription and support revenue increased by 19% compared to Q3 2023. The company is raising its total revenue guidance by $6 million to a range of $733 million to $735 million.

• Total revenue reached $186 million, a 17% increase year-over-year.
• Subscription and support revenue grew to $171 million, up 19% year-over-year.

Lyft reported a strong Q3 2024, with record active riders and rides. Gross Bookings increased by 16% year-over-year, and revenue was up by 32%. The company also raised its full-year outlook.

• Gross Bookings reached $4.1 billion, a 16% increase year-over-year.
• Revenue was $1.5 billion, up 32% year-over-year.

F&G Annuities & Life reported a net loss of $10 million for Q3 2024, but adjusted net earnings were $156 million, up from $120 million in Q3 2023. Gross sales increased by 39% year-over-year, driven by record retail channel sales. Assets under management before flow reinsurance reached a record $62.9 billion.

• Gross sales of $3.9 billion, an increase of 39% over the third quarter 2023, primarily driven by record retail channel sales
• Assets under management before flow reinsurance of $62.9 billion, an increase of 20% over the third quarter 2023

Freshworks reported a strong third quarter with revenue of $186.6 million, a 22% year-over-year increase. The company saw improvements in net cash provided by operating activities margin to 23% and free cash flow margin to 21%.

• Revenue grew 22% year-over-year to $186.6 million.
• GAAP loss from operations was $(38.9) million.

Ionis Pharmaceuticals reported a decrease in revenue for the third quarter of 2024 compared to the same period last year, but the company is making significant progress with the launch of WAINUA and advancements in its pipeline, including regulatory submissions and positive study data.

• Revenue decreased by 7% compared to the same period last year, but increased by 3% for the nine months ended September 30, 2024.
• Operating expenses increased due to investments in late-stage development and commercialization efforts.

Southwest Gas Holdings reported third quarter 2024 consolidated net income of $0.3 million, or less than one cent per diluted share, and adjusted consolidated net income of $6.8 million, or $0.09 per diluted share. The utility reported third quarter 2024 net income of $0.6 million.

• Utility earnings were strong in 2024, with 9% year-to-date earnings growth year-over-year.
• The company expects to finish within the top half of its full-year utility net income guidance range.

Schneider National reported Q3 2024 operating revenues of $1.3 billion, a decrease of 3% compared to $1.4 billion in 2023. Income from operations decreased by 8% to $43.1 million, and diluted earnings per share were $0.17, with adjusted diluted earnings per share at $0.18. The company updated its full-year adjusted diluted earnings per share guidance to $0.66 - $0.72 and net capital expenditures guidance to approximately $330.0 million.

• Dedicated and Intermodal businesses showed resilience, while Logistics maintained profitable operations.
• Dedicated performed well with a robust new business pipeline.

Enact Holdings reported a net income of $181 million, or $1.15 per diluted share, and an adjusted operating income of $182 million, or $1.16 per diluted share. The company's insurance-in-force reached a new peak, and strong bottom-line performance fueled the ability to deliver for policyholders, invest in the business, and return capital to shareholders.

• Net income was $181 million, or $1.15 per diluted share.
• Adjusted operating income was $182 million, or $1.16 per diluted share.

Grand Canyon Education reported a revenue of $238.3 million for the third quarter of 2024, a 7.4% increase compared to the same period in 2023. The increase was primarily due to higher enrollments at Grand Canyon University and off-campus sites, as well as an increase in revenue per student. Net income increased by 16.0% to $41.5 million, and diluted net income per share was $1.42.

• Service revenue increased by 7.4% year over year to $238.3 million.
• Partner enrollments totaled 127,977, compared to 123,165 in the prior year.

White Mountains reported a strong third quarter, with adjusted book value per share up 6% and 11% year-to-date. Ark produced a 79% combined ratio, and Bamboo doubled managed premiums. MediaAlpha's share price increased, producing an unrealized gain.

• Adjusted book value per share increased by 6% in Q3 2024 and 11% year-to-date.
• Ark achieved a 79% combined ratio with $374 million in gross written premiums, up 49% year-over-year.

Inter Parfums reported record third-quarter results for 2024, with net sales reaching $425 million, a 15% increase compared to the previous year. Diluted EPS was $1.93, up 16% from $1.66 in 2023. The company's performance was driven by the global fragrance market's strength and the successful integration of new brands.

• Net sales for the third quarter reached a record $425 million, a 15% increase year-over-year.
• Diluted EPS increased by 16% to $1.93, compared to $1.66 in the same period last year.

Six Flags Entertainment Corporation reported a net revenue of $1.35 billion and a net income of $111 million for the third quarter of 2024, which includes the impact of the merger with Cedar Fair. The company is targeting at least $800 million of annual unlevered pre-tax free cash flow by 2027.

• Total operating days were 2,585, with 1,591 contributed by legacy Six Flags.
• Net revenues reached $1.35 billion, including $558 million from legacy Six Flags operations.

ScottsMiracle-Gro reported an 11% increase in total company net sales for the fourth quarter, driven by a 54% increase in U.S. Consumer net sales. However, Hawthorne segment sales decreased by 46%. The company reported a GAAP net loss of $244.0 million, an improvement from the prior year's loss of $468.4 million.

• U.S. Consumer fiscal 2024 sales up 6 percent in line with guidance; POS units up 9 percent year-over-year.
• Company exceeds free cash flow target of $1 billion over two years through fiscal 2024; Net leverage at 4.86x.

Sterling Infrastructure reported a 6% increase in revenue and a 56% increase in diluted EPS for Q3 2024. Gross profit margins reached a new record of 21.9%.

• Delivered 6% revenue growth and a 56% increase in diluted EPS.
• Gross profit margins reached a new record of 21.9%.

SiTime reported strong Q3 2024 results with a 62% increase in revenue compared to the year-ago period, reaching $57.7 million. All market segments experienced double-digit sequential growth, driven by a focus on high-value applications and differentiated product offerings. The company achieved a GAAP gross profit of $29.5 million and a non-GAAP net income of $9.6 million.

• Revenue increased by 62% year-over-year, reaching $57.7 million.
• All market segments experienced double-digit sequential growth.

Black Hills Corp. announced its Q3 2024 financial results, with earnings of $0.35 per share. The company reaffirmed its 2024 earnings guidance range of $3.80 to $4.00 per share. New customer rates were approved and implemented at the Arkansas natural gas utility, and a settlement agreement was filed for new customer rates at the Iowa natural gas utility. Key financing activities for 2024 were completed, achieving the long-term capitalization target.

• Reaffirmed 2024 earnings guidance range of $3.80 to $4.00 per share.
• Received approval of and implemented new customer rates at Arkansas natural gas utility.

Brink's Q3 2024 results showed a 3% revenue increase, driven by 26% organic growth in ATM managed services and digital retail solutions. However, a strengthening US dollar and cyclical market headwinds in global services partially offset this growth. Profits were affected by these revenue factors and the timing of a large security loss. Cash generation improved through better capital efficiency and working capital management.

• Delivered strong 26% organic growth in AMS and DRS, driven by customer demand and whitespace opportunities.
• Higher-margin, recurring revenue businesses (AMS and DRS) now represent over 23% of total company revenue.

Clarivate's Q3 2024 revenues decreased by 3.9% to $622.2 million, with a net loss of $65.6 million. The company's performance was impacted by lower transactional sales and the divestiture of Valipat. As a result of the recent CEO transition and the work being done under the Value Creation Plan, the Company has removed its forward-looking outlook for 2024.

• Revenues decreased by 3.9% to $622.2 million.
• Organic revenues decreased by 2.6%, with subscription revenue growth offset by declines in re-occurring and transactional revenues.

EnerSys reported net sales of $883.7 million and diluted EPS of $2.01. The company's gross margin increased by 190 basis points to 28.5%. They were also selected for a $199 million Department of Energy award negotiation.

• Net sales were $884M, down 2%, with Motive Power strength offset by Communications and Class 8 Transportation pressure.
• Energy Systems improved with net sales +6% sequentially and backlog increasing for the second consecutive quarter.

Ormat Technologies reported a net income of $22.1 million and an adjusted EBITDA of $137.7 million for Q3 2024. The company narrowed its full-year revenue guidance and increased its full-year adjusted EBITDA guidance, reflecting strong financial results. The company also announced the commercial operation of its largest storage project to date.

• Electricity segment revenues increased due to the Enel assets and higher generation and pricing at Puna.
• Product segment backlog stands at approximately $165.0 million as of November 5, 2024.

Kodiak Gas Services announced third quarter 2024 financial results, featuring record quarterly Adjusted EBITDA of $168.4 million and Free Cash Flow of $52.5 million. The company raised full-year 2024 Adjusted EBITDA guidance to a range of $600 to $610 million and provided an early outlook on 2025 Adjusted EBITDA.

• Contract Services segment revenue was $284.3 million with Adjusted Gross Margin Percentage of 66.0%.
• Net loss of $6.2 million included a $9.9 million long-lived asset impairment, a $10.4 million loss on asset sales and a $20.3 million non-cash, mark-to-market loss on interest rate hedges.

Tanger reported a strong third quarter with positive leasing spreads for the 11th consecutive quarter. The company increased its full-year guidance and maintained a strong balance sheet with ample liquidity.

• Net income available to common shareholders was $0.22 per share, or $24.6 million.
• FFO available to common shareholders was $0.54 per share, or $62.7 million.

Kinetik Holdings Inc. reported a strong third quarter in 2024, with a 94% increase in net income year-over-year and a 23% increase in Adjusted EBITDA. The company raised its full-year Adjusted EBITDA guidance and tightened its Capital Expenditures guidance. Kinetik also increased its quarterly cash dividend and expanded its equity interest in EPIC Crude Holdings, LP.

• Net income increased by 94% year-over-year to $83.7 million.
• Adjusted EBITDA increased by 23% year-over-year to $265.7 million.

Mueller Water Products reported a 15.5% increase in net sales to $348.2 million for the fourth quarter of 2024, with adjusted EBITDA increasing by 30.9% to $72.5 million. The company's performance was driven by higher volumes and pricing across most product lines, as well as improved manufacturing performance and disciplined SG&A spending. The company is introducing its fiscal 2025 consolidated net sales guidance to be between $1,340 million and $1,360 million, or an increase of 1.9 to 3.4 percent compared with the prior year.

• Net sales increased 15.5 percent to $348.2 million compared to the prior year quarter.
• Adjusted EBITDA increased 30.9 percent to $72.5 million compared to the prior year quarter.

Everus Construction Group reported a strong third quarter with a 6.1% increase in revenues to $761.0 million and a 16.1% increase in net income to $41.8 million. The company's EBITDA increased by 12.1% to $65.0 million, and backlog reached a record $2.88 billion. The company reiterated its full-year guidance for revenue and EBITDA.

• Revenues increased by 6.1% to $761.0 million.
• Net income increased by 16.1% to $41.8 million, with a net income margin of 5.5%.

Power Integrations reported third-quarter results with revenues of $115.8 million, GAAP EPS of $0.25, and non-GAAP EPS of $0.40. The company announced a five percent dividend increase and a $50 million share-repurchase authorization.

• Net revenues for the third quarter were $115.8 million, down eight percent from the third quarter of 2023.
• GAAP net income for the third quarter was $14.3 million or $0.25 per diluted share.

Perrigo reported a decrease in net sales by 3.2% to $1.1 billion, with organic net sales decreasing by 2.4%. However, the company saw significant growth in adjusted operating income, which increased by 21.3% to $182 million. Adjusted diluted EPS increased by 26.6% to $0.81. The infant formula business is recovering, with net sales growth of 3% compared to the prior year quarter and 58% sequentially.

• Net sales decreased by 3.2% to $1.1 billion, with a 2.4% decrease in organic net sales.
• Adjusted operating income increased by 21.3% to $182 million.

DoubleVerify reported a strong third quarter in 2024, with an 18% year-over-year increase in revenue to $169.6 million. The company achieved a net income of $18.2 million and an adjusted EBITDA of $60.2 million, representing a 35% adjusted EBITDA margin. The company also announced a new authorization of $200.0 million for additional common stock repurchases.

• Total revenue increased by 18% year-over-year to $169.6 million.
• Activation revenue increased by 18% year-over-year to $96.8 million.

Hecla Mining Company reported third quarter 2024 financial results with revenues of $245.1 million and net income applicable to common stockholders of $1.6 million, or $0.00 per share. The company produced 3.6 million silver ounces and reduced total debt by $50.6 million.

• Produced 3.6 million silver ounces and 32,280 ounces of gold.
• Revenues of $245.1 million, with 45% from silver and 32% from gold.

Ashland reported a one percent increase in sales to $522 million for the fourth quarter of fiscal year 2024. Net income rose to $16 million, and adjusted EBITDA increased by 68 percent to $124 million, primarily due to sales and production volume recovery, improved product mix, and deflationary raw materials. The company issued its outlook for full-year fiscal 2025 and provided an update on portfolio optimization.

• Sales increased by one percent to $522 million compared to the prior-year quarter.
• Net income improved to $16 million, up from a net loss of $4 million in the prior-year quarter.

Denali Therapeutics reported its Q3 2024 financial results, highlighting progress in its Transport Vehicle (TV)-enabled portfolio, particularly the Enzyme TV (ETV) franchise with tividenofusp alfa for MPS II, and advancements in the DNL126 study for MPS IIIA.

• On track to file for accelerated approval of tividenofusp alfa in MPS II in early 2025 after a successful meeting with the FDA in the third quarter.
• Preliminary data from Phase 1/2 study of DNL126 in MPS IIIA demonstrate a robust reduction from baseline in CSF heparan sulfate levels, including normalization.

Veracyte announced strong third-quarter results with a 29% increase in total revenue to $115.9 million and a 34% increase in testing revenue to $109.5 million. The company achieved profitability and cash generation, driven by growth in Decipher and Afirma tests. Veracyte is raising its full-year 2024 total revenue guidance to $442 million to $445 million.

• Total revenue increased by 29% to $115.9 million, with total volume up by 20% to 39,032 tests.
• Testing revenue grew by 34% to $109.5 million, with testing volume up by 24% to 36,792 tests.

MGE Energy reported GAAP earnings of $40.9 million, or $1.13 per share, for the third quarter of 2024, compared to $37.9 million, or $1.05 per share, for the same period in the prior year. The increase in electric net income was driven by higher electric investments in rate base and lower fuel costs.

• GAAP earnings for Q3 2024 were $40.9 million, or $1.13 per share.
• This compares to $37.9 million, or $1.05 per share, for the same period last year.

Genworth Financial reported a net income of $85 million and adjusted operating income of $48 million for the third quarter of 2024. The company continued to advance its strategic priorities, including progress on its LTC multi-year rate action plan and expansion of the CareScout Quality Network. Enact's strong performance contributed to the results, with $148 million in adjusted operating income and $81 million in capital returns to Genworth. The company also executed $36 million in share repurchases during the quarter.

• Achieved $124M in gross incremental premium approvals for the LTC multi-year rate action plan.
• Expanded the CareScout Quality Network to 49 states, covering over 75% of the aged 65-plus Census population.

NMI Holdings, Inc. reported a net income of $92.8 million, or $1.15 per diluted share, for the third quarter ended September 30, 2024. The company also entered into new reinsurance agreements for business originated between January 1, 2025, and December 31, 2027.

• Primary insurance-in-force at quarter end was $207.5 billion, compared to $203.5 billion at the end of the second quarter.
• Net premiums earned were $143.3 million, compared to $141.2 million in the second quarter.

Marriott Vacations Worldwide reported a 5% increase in consolidated vacation ownership contract sales to $459 million compared to Q3 2023. The company is also implementing cost efficiency initiatives expected to drive $50 to $100 million in annual savings over the next two years.

• Consolidated Vacation Ownership contract sales increased 5% compared to the third quarter of 2023 to $459 million.
• Net income attributable to common stockholders was $84 million and fully diluted earnings per share was $2.12.

Acadia Pharmaceuticals reported a successful third quarter in 2024, with total revenues of $250.4 million, reflecting an 18% increase year-over-year. The company is on track to achieve over $1 billion in annualized sales in 2025, driven by the growth of NUPLAZID and DAYBUE.

• Total revenues reached $250.4 million, an 18% increase compared to the third quarter of 2023.
• NUPLAZID net product sales were $159.2 million, representing a 10% year-over-year increase.

Amedisys reported a net service revenue increase of $31.5 million to $587.7 million compared to the previous year. Net income attributable to Amedisys, Inc. was $16.9 million, inclusive of merger-related expenses. Adjusted net income per diluted share was $1.00, compared to $0.98 in the prior year.

• Net service revenue increased to $587.7 million compared to $556.2 million in the previous year.
• Net income attributable to Amedisys, Inc. was $16.9 million, inclusive of merger-related expenses.

Avista Corp. announced financial results for the third quarter of 2024, reflecting continued improvement from 2023. However, the company lowered its consolidated earnings guidance due to lower-than-expected valuations in its other businesses.

• Quarterly results demonstrate continued improvement at core utility from 2023.
• Expect to be at the low end of Avista Utilities guidance range.

Amicus Therapeutics announced strong Q3 2024 results, driven by excellent commercial performance of Galafold and Pombiliti + Opfolda, exceeding expectations and achieving non-GAAP profitability for the full year 2024.

• Total revenue reached $141.5M, a 37% increase year-over-year.
• Galafold revenue was $120.4M, up 20% year-over-year.

American States Water Company reported an increase in earnings per share to $0.95 for Q3 2024, compared to $0.85 in Q3 2023. This increase was primarily due to higher earnings at the water utility subsidiary, Golden State Water Company. The company also reached settlement agreements in connection with water and electric general rate cases, authorizing significant capital investments.

• Q3 2024 earnings per share increased to $0.95, up from $0.85 in Q3 2023.
• Golden State Water Company's performance drove the earnings increase with a $0.12 per share contribution.

Recursion Pharmaceuticals reported its Q3 2024 financial results, with a focus on the anticipated closing of the business combination with Exscientia. The company highlighted multiple clinical trial milestones and an expanded collaboration with Google Cloud. Total revenue increased to $26.1 million, driven by the Roche & Genentech partnership and a $30 million acceptance fee for a neuroscience phenomap.

• Multiple clinical trial milestones were achieved, including Phase 2 data for CCM and first patient dosed for C. difficile infection Phase 2 trial.
• First neuroscience phenomap was optioned by Roche-Genentech for $30 million, potentially exceeding $500 million.

Enovis reported strong third-quarter results with a 21% increase in sales and significant growth in the Reconstructive segment. The company is focusing on shifting from integration to growth, supported by new product introductions.

• Third-quarter sales grew by 21% on a reported basis.
• Reconstructive sales increased by 57% year-over-year on a reported basis.

FS KKR Capital Corp. announced its financial results for the third quarter ended September 30, 2024. The company reported Earnings per Share of $0.57 and adjusted net investment income of $0.74 per share. The board of directors declared a fourth quarter distribution of $0.70 per share.

• Net investment income was $0.77 per share.
• Adjusted net investment income was $0.74 per share.

LXP Industrial Trust reported a net income of $4.7 million, or $0.02 per diluted common share, and Adjusted Company FFO of $46.7 million, or $0.16 per diluted common share. The company experienced a 5.4% increase in Same-Store NOI and completed new leases and lease extensions totaling 0.7 million square feet.

• Net Income attributable to common shareholders was $4.7 million, or $0.02 per diluted common share.
• Adjusted Company FFO was $46.7 million, or $0.16 per diluted common share.

Janux Therapeutics reported a net loss of $28.1 million for the third quarter of 2024, with cash and cash equivalents and short-term investments totaling $658.0 million. The company is focused on enrolling participants in clinical trials for JANX007 and JANX008 and anticipates providing an update on the JANX007 program by year end.

• Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.
• An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024.

TripAdvisor reported flat revenue of $532 million year-over-year for Q3 2024. Net income increased to $39 million, or $0.27 per share, while non-GAAP net income was $72 million, or $0.50 per share. All three segments—Brand TripAdvisor, Viator, and TheFork—achieved profitability.

• Revenue remained flat at $532 million compared to the previous year.
• Net income increased to $39 million, or $0.27 per share.

Rapid7 announced positive momentum in Q3 2024, with revenue and operating income exceeding guided ranges. The company saw growth in its threat detection and response business and strong demand for its consolidated offerings. ARR increased by 6% year-over-year to $823 million, and total revenue grew by 8% to $215 million.

• Annualized recurring revenue (ARR) reached $823 million, a 6% increase year-over-year.
• Total revenue was $215 million, up 8% year-over-year, with product subscriptions revenue of $206 million, also up 8%.

Coeur Mining reported a strong third quarter in 2024, marked by double-digit production increases and cost reductions, leading to a net income of $49 million and adjusted EBITDA of $126 million. The company also generated strong free cash flow and announced the acquisition of SilverCrest to create a leading global silver company.

• Gold production increased by 21% and silver production increased by 15% due to higher production at all four operations.
• Revenue increased by 41% quarter-over-quarter to $313 million and adjusted EBITDA increased by 140% quarter-over-quarter to $126 million.

Tandem Diabetes Care reported a successful third quarter in 2024, achieving the highest quarterly sales in the company's history. Worldwide GAAP sales increased by 31% to $244.0 million compared to Q3 2023. The company also demonstrated positive Adjusted EBITDA and a return to positive free cash flow, leading to an increase in full year 2024 sales guidance.

• Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023.
• Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023.

Atlanta Braves Holdings reported a 7% increase in total revenue for the third quarter of 2024, reaching $291 million. Baseball revenue increased by 7% to $273 million, and mixed-use development revenue grew by 12% to $17 million. However, operating income decreased by 59% to $6.4 million due to increased baseball operating costs.

• Total revenue grew to $291 million, a 7% increase from the prior year period.
• Baseball revenue increased 7% to $273 million.

Clover Health reported strong third quarter 2024 financial results, with significant improvements in GAAP Net Loss and Adjusted EBITDA. The company delivered 9% total revenue growth year-to-date compared to the prior year period. Increased full-year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million.

• GAAP Net loss from continuing operations improved to $8.8 million from $33.6 million in the third quarter of 2023.
• Adjusted EBITDA increased to $19.3 million from $2.7 million in the third quarter of 2023.

CoreCivic reported a 2% increase in total revenue, reaching $491.6 million. Net income increased by 52% to $21.1 million, with diluted earnings per share of $0.19. The company raised its full year financial guidance, reflecting strong operating momentum and cost management.

• Total revenue increased by 2% to $491.6 million.
• Net income rose by 52% to $21.1 million.

Axcelis announced third quarter revenue of $256.6 million, with a net income of $48.6 million, or $1.49 per diluted share. The company anticipates a near term digestion of mature node capacity through the first half of 2025.

• Third quarter revenue was $256.6 million.
• Gross margin for the quarter was 42.9%.

Upwork reported a 10% year-over-year revenue increase and a record net income in Q3 2024. The company is raising its full-year 2024 revenue and adjusted EBITDA guidance and authorized a new $100 million share repurchase program.

• Revenue grew 10% year-over-year to $193.8 million.
• Net income reached an all-time high of $27.8 million, up 70% year-over-year.

OPENLANE reported a revenue of $448 million, driven by a 6% volume growth. The company's income from continuing operations was $28 million, with an adjusted EBITDA of $75 million. The marketplace segment showed continued resiliency and profitability, with significant adjusted EBITDA growth and a Gross Merchandise Value increase of 12% to nearly $7 billion.

• Total revenue reached $448 million, an 8% increase year-over-year.
• Consolidated income from continuing operations was $28 million, with Marketplace contributing $5 million.

LiveRamp announced strong Q2 FY25 results with revenue and operating income exceeding expectations. Revenue grew by 16% year-over-year, driven by the Data Collaboration Platform. The company continues to scale its clean room network and enhance its platform to facilitate first-party data activation for customers.

• Total revenue was $185 million, up 16% year-over-year.
• GAAP operating income was $7 million, while non-GAAP operating income was $41 million.

Vishay Intertechnology reported Q3 2024 revenues of $735.4 million. The GAAP loss per share was ($0.14), while adjusted EPS was $0.08 per share. The book-to-bill ratio was 0.88, with semiconductors at 0.79 and passive components at 0.97.

• Q3 2024 revenues reached $735.4 million.
• Gross margin was 20.5%, impacted by Newport's addition by approximately 150 basis points.

AvidXchange reported a solid third quarter with a 14.3% increase in revenue, significant expansion in non-GAAP gross margin to 74.5%, and adjusted EBITDA margin at 20.7%. Net cash from operating activities increased significantly due to the replacement of higher interest rate debt with a new credit facility. The company also revised its 2024 revenue and adjusted EBITDA outlook upward.

• Revenue increased by 14.3% year-over-year.
• GAAP net income was $4.0 million, compared to a net loss of $(8.1) million in the third quarter of 2023.

EVERTEC reported a 22% increase in revenue to $211.8 million and a 146% increase in GAAP net income attributable to common shareholders to $24.7 million, or $0.38 per diluted share, for the third quarter ended September 30, 2024. The results were driven by organic growth across all segments and the contribution from the Sinqia acquisition. The company also announced the acquisition of Grandata, a data analytics company operating in Mexico.

• Revenue increased 22% to $211.8 million.
• GAAP Net Income attributable to common shareholders increased 146% to $24.7 million, with earnings per diluted share increasing 153% to $0.38.

VSE Corporation reported strong Q3 2024 results, highlighted by record revenue in the Aviation segment. The Fleet segment is expected to improve in Q4. The company completed an equity offering to finance the acquisition of Kellstrom Aerospace.

• Total revenues increased by 18.3% to $273.6 million.
• Aviation segment revenue increased 34% year-over-year to a record $203.6 million.

Soleno Therapeutics reported a net loss of $76.6 million for the third quarter ended September 30, 2024. The FDA accepted the NDA for DCCR with a PDUFA target action date of December 27, 2024.

• The FDA accepted the NDA for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) and granted Priority Review.
• The FDA's target action date is December 27, 2024.

Innovative Industrial Properties (IIP) reported a decrease in total revenues to $76.5 million for the third quarter ended September 30, 2024, compared to $77.8 million for the same period in 2023. Net income attributable to common stockholders was $39.7 million, or $1.37 per share. The company paid a quarterly dividend of $1.90 per common share on October 15, 2024.

• Total revenues for Q3 2024 were $76.5 million, a 1.7% decrease compared to Q3 2023.
• Net income attributable to common stockholders for Q3 2024 was $39.7 million, or $1.37 per share.

Kennametal reported a decrease in sales and earnings per share for the first quarter of fiscal year 2025. Sales decreased by 2% to $482 million, and EPS decreased to $0.28. However, the company saw strong cash flow from operations, and returned approximately $31 million to shareholders through share repurchases and dividends.

• Sales decreased by 2% year-over-year to $482 million due to softer market conditions.
• EPS decreased to $0.28, with adjusted EPS at $0.29.

Amphastar Pharmaceuticals reported a net revenue increase of 6% to $191.2 million for the third quarter of 2024. GAAP net income was $40.4 million, and adjusted non-GAAP net income reached $49.6 million. The company's growth was driven by sales, particularly from BAQSIMI® and Primatene MIST®.

• Net revenues for Q3 2024 reached $191.2 million.
• GAAP net income for Q3 2024 was $40.4 million, or $0.78 per share.

Global Net Lease reported a revenue of $196.6 million and a net loss attributable to common stockholders of $76.6 million. The company achieved $85 million in cost synergies, reduced net debt by $445 million year-to-date, and increased portfolio occupancy from 94% to 96%. GNL reaffirms its full-year 2024 guidance.

• Closed plus disposition pipeline totaled $950 million at a cash cap rate of 7.1%.
• Achieved $85 million in cost synergies, significantly exceeding initial projection of $75 million.

Arcutis Biotherapeutics reported Q3 2024 financial results, featuring a 45% increase in product revenue compared to the previous quarter, driven by strong demand for ZORYVE products and improved gross-to-net adjustments. The company also highlighted key regulatory milestones, including the acceptance of the sNDA for ZORYVE foam and approval in Canada, as well as advancements in their pipeline programs.

• Net product revenues for the ZORYVE franchise reached $44.8 million, demonstrating a 452% increase compared to Q3 2023.
• Blended gross-to-net improved to the low 50 percent range, up from the high 50 percent range in the previous quarter.

Celldex reported a net loss of $42.1 million, or ($0.64) per share, for the third quarter of 2024. Total revenue was $3.2 million, and research and development expenses were $45.3 million. Cash, cash equivalents, and marketable securities totaled $756.0 million as of September 30, 2024.

• Cash, cash equivalents and marketable securities were $756.0 million as of September 30, 2024.
• Total revenue was $3.2 million in the third quarter of 2024.

CSG Systems International reported a 2.9% increase in revenue to $295.1 million for Q3 2024. GAAP EPS increased to $0.67, and non-GAAP EPS rose to $1.06. The company is raising its 2024 profitability and non-GAAP EPS guidance targets for a second consecutive quarter and plans to return $100+ million to shareholders via dividends and share repurchases in each of 2024 and 2025.

• Total revenue was $295.1 million.
• GAAP operating income was $31.8 million, with a margin of 10.8%.

Cadre Holdings reported net sales of $109.4 million and a net income of $3.7 million for the third quarter of 2024. The results were impacted by cybersecurity incidents that temporarily disrupted business operations. The company is focused on long-term growth through innovation, strategic acquisitions, and maintaining market leadership.

• Net sales for the third quarter were $109.4 million, compared to $125.1 million in the same period of 2023.
• Gross profit was $40.0 million, with a gross profit margin of 36.6%.

Immunocore reported a strong third quarter with KIMMTRAK net revenues of $80.2 million, a 28% increase over 3Q 2023. The company also reported positive net income and advanced its pipeline with ongoing Phase 3 trials and presentations of clinical data.

• KIMMTRAK net revenues reached $80.2 million, demonstrating 28% growth compared to 3Q 2023.
• Phase 3 trials for cutaneous melanoma (PRISM-MEL-301 and TEBE-AM) are ongoing, and the Phase 3 trial in adjuvant uveal melanoma (ATOM) is set to begin randomization in 4Q 2024.

LegalZoom reported a 1% increase in revenue year-over-year, driven by subscription revenue growth of 5%. The company achieved a record net income of $11.1 million and an adjusted EBITDA of $47.1 million. They are focusing on subscription offerings and pricing updates to attract high-value customers.

• Total revenue increased by 1% year-over-year, reaching $168.6 million.
• Subscription revenue grew by 5% year-over-year, totaling $110.7 million.

RLJ Lodging Trust reported solid third-quarter results, exceeding expectations with RevPAR growth two times the industry average. The company executed key initiatives, including addressing near-term maturities, completing conversions, repurchasing stock, raising the quarterly dividend by 50%, and reaffirming its outlook.

• Portfolio Comparable RevPAR of $145.23; an increase of 2.0% from last year
• Comparable Hotel Revenue of $344.7 million; an increase of 3.0% from last year

SSR Mining reported a net income attributable to shareholders of $10.6 million, or $0.05 per diluted share, despite challenges at Çöpler and Seabee. Adjusted net income was $6.4 million, or $0.03 per diluted share. The company spent $48.3 million on Çöpler remediation in Q3, bringing the total since April 1 to $103.3 million. They held $334.3 million in cash and cash equivalents.

• Third quarter 2024 production was 97,429 gold equivalent ounces with operations at Çöpler remaining suspended.
• Net income attributable to SSR Mining shareholders in the third quarter of 2024 was $10.6 million, or $0.05 per diluted share.

Xenia Hotels & Resorts reported a net loss of $7.1 million for the third quarter of 2024. Adjusted EBITDAre decreased by 4.4% compared to the same quarter in 2023, and Adjusted FFO per Diluted Share decreased by 3.8%. Same-Property RevPAR increased by 1.5%, while Same-Property Hotel EBITDA decreased by 6.3%.

• Net loss attributable to common stockholders was $7.1 million, or $0.07 per share.
• Adjusted EBITDAre decreased 4.4% compared to the third quarter of 2023, reaching $44.3 million.

Redwire Corporation reported a 9.6% increase in revenue to $68.6 million for Q3 2024. The company's contracted backlog increased by 30.2% year-over-year to $330.1 million. However, the company experienced a net loss of $(21.0) million, which includes a loss contingency of $8.0 million related to a securities lawsuit, while adjusted EBITDA was $2.4 million.

• Revenues increased by 9.6% year-over-year to $68.6 million.
• Contracted Backlog increased by 30.2% year-over-year to $330.1 million.

UMH Properties, Inc. reported an increase in total income and net income attributable to common shareholders for the quarter ended September 30, 2024. Normalized Funds from Operations Attributable to Common Shareholders also increased compared to the same period in the previous year. The company also updated its 2024 guidance for normalized FFO.

• Total Income for Q3 2024 increased by 8% to $60.7 million compared to $56.0 million for Q3 2023.
• Net Income Attributable to Common Shareholders was $8.2 million, or $0.11 per diluted share, compared to a Net Loss of $5.8 million, or $0.09 per diluted share, for Q3 2023.

Fastly reported Q3 2024 financial results with revenue of $137.2 million, a GAAP net loss of $38.0 million, and a non-GAAP net income of $2.4 million. The company's revenue saw a 7% year-over-year increase, driven by strength in large customers and share gains outside the top ten. Adjusted EBITDA reached a record $13.3 million.

• Total revenue reached $137.2 million, a 7% increase year-over-year.
• GAAP net loss was $38.0 million, while non-GAAP net income was $2.4 million.

Praxis Precision Medicines reported a net loss of $51.9 million for Q3 2024, with research and development expenses increasing to $41.9 million. The company's cash, cash equivalents, and marketable securities totaled $411.2 million as of September 30, 2024, providing a runway into 2027. Key clinical programs, including ulixacaltamide, vormatrigine, and relutrigine, are advancing towards registrational readiness.

• Advanced relutrigine into late-stage development, marking a third molecule with blockbuster potential.
• Finalized the operational plan to complete the interim analysis for Essential3 Study 1 for ulixacaltamide in mid-Q1 2025.

Veeco Instruments Inc. announced financial results for the third quarter ended September 30, 2024. The company's revenue was $184.8 million, compared to $177.4 million in the same period last year. GAAP net income was $22.0 million, or $0.36 per diluted share, compared to $24.6 million, or $0.42 per diluted share in the same period last year. Non-GAAP net income was $28.3 million, or $0.46 per diluted share, compared to $31.0 million, or $0.53 per diluted share in the same period last year.

• Revenue of $184.8 million, compared with $177.4 million in the same period last year
• GAAP net income of $22.0 million, or $0.36 per diluted share, compared with $24.6 million, or $0.42 per diluted share in the same period last year

Liberty Latin America reported Q3 2024 results with revenue of $1.1 billion. The company is focused on connecting communities and driving broadband and postpaid mobile penetration. Transformation programs are gaining momentum, and the company expects a strong performance in Q4 driven by B2B growth and recovery in Puerto Rico.

• C&W Caribbean: Flat YoY revenue performance, including $5m negative impact from Hurricane Beryl, and YoY reported and rebased Adj. OIBDA growth of 5%.
• C&W Panama: Strong operating and financial progress with 12,000 broadband and mobile postpaid additions and YoY Adj. OIBDA growth of 17%.

Xencor reported Q3 2024 financial results, including revenues of $10.7 million and a net loss of $45.1 million. The company highlighted progress in its clinical pipeline, particularly in oncology and autoimmune programs, and announced Amgen's advancement of xaluritamig into Phase 3 development. Xencor's cash, cash equivalents, and marketable debt securities totaled $754.3 million as of September 30, 2024.

• Xencor announced new clinical development plans for plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to target autoimmune diseases.
• Xencor's public offering raised $201.3 million in gross proceeds.

Viasat released its second quarter fiscal year 2025 financial results in a letter to shareholders.

• Second quarter fiscal year 2025 financial results were published.
• Results were shared in a letter to shareholders.

Kennedy Wilson reported a GAAP Net Loss to Common Shareholders of $77.4 million. However, the company saw growth in investment management fees and made progress on key initiatives such as asset stabilizations and non-core asset dispositions.

• Estimated Annual NOI grew to $492 million, driven by asset stabilizations and partly offset by non-core asset dispositions.
• Investment Management fees grew by 39% to $22 million, driven by higher Fee-Bearing Capital and new originations from the Debt Investment Platform.

Vital Energy reported a strong third quarter in 2024, marked by record production and the successful acquisition of Point Energy. The company increased its full-year total and oil production guidance due to the outperformance of acquired assets and optimized operations. They closed the Point Energy acquisition for $815 million.

• Closed the Point Energy acquisition for $815 million.
• Reported net income of $215.3 million and cash flows from operating activities of $246.2 million.

Tutor Perini reported a net loss for Q3 2024, primarily due to net charges of approximately $152 million related to dispute resolutions. However, the company achieved a record backlog of $14.0 billion and anticipates strong cash flow in the coming periods, expecting to return to profitability in 2025.

• Record backlog of $14.0 billion at the end of Q3 2024, a 35% increase compared to Q2 2024.
• Loss from construction operations was $106.8 million for Q3 2024.

AMC Entertainment Holdings, Inc. reported its Third Quarter 2024 results, with total revenues of $1,348.8 million and a net loss of $(20.7) million. The company highlighted improvements in financial metrics compared to the previous quarter, including a 31% increase in total revenues and a significant reduction in net loss. Strategic debt transactions were completed to extend maturities and reduce outstanding debt. While some metrics were behind the previous year, the company expressed optimism for the upcoming movie slate and future box office performance.

• Total revenues reached $1,348.8 million.
• Net loss amounted to $(20.7) million, improving from the previous quarter.

Arcus Biosciences reported Q3 2024 financial results with revenues of $48 million and a net loss of $92 million. The company's cash, cash equivalents, and marketable securities totaled $1.1 billion, expected to fund operations into mid-2027. Key pipeline updates were provided, including progress in casdatifan and domvanalimab development.

• Presented data from the Phase 1/1b ARC-20 study of casdatifan at the 2024 EORTC-NCI-AACR Symposium, showcasing a low rate of primary progression and promising objective response rate in heavily pretreated patients with clear-cell renal cell carcinoma.
• Announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig in patients with immuno-oncology (IO)-naive ccRCC.

Encore Capital Group reported a strong third quarter, with global portfolio purchases up 23% to $282 million and global collections up 18% to $550 million. The company raised its 2024 guidance, anticipating global portfolio purchasing to exceed $1,250 million and year-over-year collections growth of approximately 15% to over $2,125 million.

• Highly favorable purchasing conditions continue in the U.S. market.
• Global portfolio purchases increased by 23% to $282 million.

Innoviva reported strong Q3 2024 financial results, driven by solid performance from core GSK royalty assets and accelerating sales from IST commercial products. The company is on track to submit an NDA for zoliflodacin to the U.S. FDA in early 2025.

• Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth.
• Innoviva Specialty Therapeutics’ (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth

Pacira BioSciences reported third quarter 2024 financial results with total revenues of $168.6 million. Net loss was $143.5 million, or $3.11 per share. Adjusted EBITDA was $54.7 million. The company is reiterating its full-year 2024 financial guidance.

• Total revenues were $168.6 million.
• EXPAREL net product sales were $132.0 million.

Kronos Worldwide, Inc. reported a net income of $71.8 million, or $.62 per share, in the third quarter of 2024, a significant improvement compared to a net loss of $20.4 million, or $.18 per share, in the third quarter of 2023. The increase was primarily due to higher income from operations, resulting from increased sales and production volumes, and lower production costs, partially offset by lower average TiO2 selling prices. Net sales increased by 22% compared to the same period in 2023, driven by higher sales volumes due to strengthening demand for TiO2.

• Net income was $71.8 million, or $.62 per share, compared to a net loss of $20.4 million, or $.18 per share, in Q3 2023.
• Net sales increased by 22% to $484.7 million, driven by higher sales volumes.

Ellington Financial's investment portfolio expanded, driven by growth in high-yielding loan portfolios. Non-QM and proprietary reverse mortgage loan businesses performed strongly, contributing to net income of $0.19 per share. Adjusted distributable earnings increased to $0.40 per share, covering dividends.

• Net income attributable to common stockholders was $16.2 million, or $0.19 per common share.
• Adjusted Distributable Earnings of $34.5 million, or $0.40 per common share.

BBSI reported strong Q3 2024 financial results, with revenues up 8% to $294.3 million and net income of $19.6 million, or $0.74 per diluted share. The company's performance was driven by growth in PEO services and strong client retention.

• Revenues increased by 8% to $294.3 million.
• Gross billings increased by 9% to $2.14 billion.

MFA Financial reported strong third quarter results, with distributable earnings of $0.37 per share. The economic book value rose approximately 1% to $14.46 per share. The company purchased or originated over $565.2 million of residential mortgage loans and added $294 million of Agency MBS.

• Distributable earnings were $0.37 per share.
• Economic book value increased by approximately 1% to $14.46 per share.

Brookdale Senior Living Inc. reported increased occupancy and same community operating income, driven by resident fee growth. The company also highlighted strategic transactions and initiatives aimed at creating value for shareholders.

• Consolidated weighted average occupancy grew 130 basis points year-over-year and 80 basis points sequentially.
• Same community operating income increased 10.1% over the prior year period, excluding prior period grant income.

Deluxe reported a slight decrease in revenue but a significant improvement in net income, driven by cost management and gains from business exits. Comparable adjusted EBITDA and EPS also showed growth, and the company narrowed its 2024 guidance within existing ranges. The company delivered another strong quarter of comparable adjusted EBITDA, EPS, and free cash flow growth, enabling net debt reduction of nearly $45 million, during the third quarter.

• Revenue decreased by 1.7%, while comparable adjusted revenue decreased by 0.7%.
• Net income improved to $8.9 million from a net loss of $8.0 million in the previous year.

Sinclair reported a strong third quarter, with total revenues increasing by 20% to $917 million. Core advertising revenues grew by 1%, and distribution revenues increased by 5%. The company's net income attributable to the company was $94 million, a significant improvement from the prior year's net loss of $46 million.

• Core advertising revenues grew by 1% year-over-year during a quarter with record political revenues.
• Political revenues reached $138 million, a 31% increase over 2020 levels.

Blend Labs, Inc. announced its third quarter 2024 financial results, achieving non-GAAP operating profitability ahead of its fourth quarter target. The company signed multi-year deals with new customers in both mortgage and consumer banking. Total company revenue was $45.2 million.

• Achieved Non-GAAP Operating Profitability, improving GAAP loss from operations to $13.3 million.
• Welcomed new customers to the platform, including Pentagon Federal Credit Union.

Wolfspeed reported a slight decrease in revenue to $194.7 million compared to $197.4 million in the first quarter of fiscal 2024. The company is focusing on streamlining its business to a 200mm pure-play, which is expected to yield $200 million in cash savings. They have also secured access to an additional $2.5 billion in liquidity.

• Consolidated revenue was approximately $195 million, with Mohawk Valley Fab contributing approximately $49 million.
• Power device design-ins reached $1.5 billion.

The Pennant Group reported a strong third quarter with a 28.9% increase in total revenue compared to the prior year quarter. GAAP diluted earnings per share were $0.20, and adjusted diluted earnings per share were $0.26. The company is well-positioned for future growth with a healthy balance sheet.

• Total revenue for the third quarter was $180.7 million, an increase of 28.9% over the prior year quarter.
• Net income for the third quarter was $6.2 million, an increase of 41.6% over the prior year quarter.

Nextdoor's Q3 2024 saw revenue growth of 17% year-over-year to $66 million, driven by improvements in the Nextdoor Ads Platform and a return to growth for enterprise advertisers. Weekly Active Users (WAU) grew by 13% year-over-year to 45.9 million. The company's adjusted EBITDA improved significantly, reaching ($1 million), and they are raising their full-year guidance for revenue and adjusted EBITDA.

• Revenue grew +17% year-over-year, driven by self-serve revenue momentum and enterprise advertisers.
• Weekly Active Users (WAU) grew +13% year-over-year, reflecting sustained organic user acquisition.

Evolus reported a 22% increase in total net revenues for Q3 2024, reaching $61.1 million, driven by higher volumes of Jeuveau®. The company narrowed its full-year revenue guidance to $260 million to $266 million and reaffirmed its expectation of non-GAAP profitability in Q4 2024 and full year 2025. Evolus also received approval for Estyme® in the European Union and anticipates the launch of Evolysse™ in the U.S. by September 2025.

• Total net revenues increased by 22% to $61.1 million compared to Q3 2023.
• Adjusted gross profit margin was 70.2%.

Corsair Gaming, Inc. reported a decrease in net revenue and a net loss for Q3 2024, with overall revenue down 16.2% year-over-year. However, the Gamer and Creator Peripherals segment saw a 13% increase in revenue. The company completed the acquisition of Fanatec and anticipates a strong 2025 with new product launches and a rebound in the components product lines.

• Net revenue decreased by 16.2% to $304.2 million compared to Q3 2023.
• Gamer and Creator Peripherals segment revenue increased by 13% year-over-year.

Kura Sushi USA reported a decrease in comparable restaurant sales and a shift from operating income to an operating loss. Total sales increased, but the company experienced a net loss, contrasting with the net income reported in the fourth quarter of 2023.

• Total sales increased to $66.0 million from $54.9 million in Q4 2023.
• Comparable restaurant sales decreased by 3.1% compared to Q4 2023.

Phibro Animal Health Corporation reported a strong first quarter with net sales increasing by 13% to $260.4 million and net income of $7.0 million. Adjusted EBITDA increased by 64% to $30.7 million, driven by strong performance in the Vaccines business and recovery in Mineral Nutrition and Performance Products. The company updated its fiscal year 2025 guidance, projecting net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.

• Net sales increased by 13% to $260.4 million.
• Net income increased to $7.0 million, a $15.0 million increase.

Aspen Aerogels reported a revenue of $117.3 million for Q3 2024, a significant increase compared to $60.8 million in Q3 2023. The company's gross margins stood at 42%, with Adjusted EBITDA margins at 22%. They have increased their 2024 financial outlook to $450 million in revenue, $9 million in net income, and $90 million in Adjusted EBITDA.

• Total revenue for Q3 2024 was $117.3 million, compared to $60.8 million in Q3 2023.
• Thermal Barrier revenue reached $90.6 million, up 176% year-over-year.

National Vision Holdings, Inc. reported a 2.9% increase in net revenue to $451.5 million, driven by new store sales and comparable store sales growth. The company experienced a net loss of $(8.4) million, or $(0.11) per share, but an adjusted EPS of $0.12. They reaffirmed their fiscal 2024 outlook for key metrics and updated capital expenditure expectations.

• Net revenue increased by 2.9% to $451.5 million.
• Comparable store sales growth was 1.4%, with adjusted comparable store sales growth of 0.9%.

Bumble Inc. reported a slight decrease in total revenue, down 0.7% to $273.6 million. Bumble app revenue also decreased by 0.7% to $220.2 million. However, Bumble app paying users increased by 10% to 2.9 million. The company reported a net loss of $849.3 million, including $892.2 million in non-cash impairment charges.

• Total revenue decreased by 0.7% to $273.6 million.
• Bumble App revenue decreased by 0.7% to $220.2 million.

Nuvation Bio reported a net loss of $41.2 million, or $(0.15) per share, and had cash, cash equivalents, and marketable securities of $549.1 million as of September 30, 2024. The company completed the NDA submission for taletrectinib and presented positive data from Phase 2 TRUST-I and TRUST-II studies.

• Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October.
• Presented positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib at the 2024 European Society of Medical Oncology (ESMO) Congress.

SolarEdge Technologies reported revenues of $260.9 million, a decrease of 2% from the prior quarter and 64% from the same quarter last year. The company faced a GAAP net loss of $1.21 billion, or $21.11 per share, and a non-GAAP net loss of $874.3 million, or $15.31 per share.

• Revenues were $260.9 million.
• Revenues from the solar segment were $247.5 million.

Astec Industries reported a decrease in net sales by 3.9% to $291.4 million. The company experienced a net loss of $6.2 million, which included an $8.4 million charge for settling a legacy litigation. Adjusted net income was $7.0 million. The company improved its cash flow, generating $22.5 million in operating cash flow and $19.9 million in free cash flow.

• Net sales decreased by 3.9% to $291.4 million.
• Net loss was $6.2 million, including an $8.4 million litigation charge; adjusted net income was $7.0 million.

Relay Therapeutics reported no revenue for Q3 2024, compared to $25.2 million in Q3 2023. Research and development expenses were $76.6 million, down from $81.5 million year-over-year. The company's net loss was $88.1 million, or $0.63 per share, compared to a net loss of $65.7 million, or $0.54 per share, in the prior year. They ended the quarter with approximately $840 million in cash, cash equivalents and investments, expected to fund operations into the second half of 2027.

• Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D.
• Planned to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025.

Plymouth Industrial REIT reported a net loss attributable to common stockholders of $15.7 million, or $(0.35) per share, compared to net income of $7.5 million, or $0.17 per share, for the same period in 2023. Consolidated total revenues were $51.9 million, compared with $49.8 million for the same period in 2023. The results were impacted by non-recurring items, including a loss on financing transaction and the impact of vacancies, offset by NOI contribution from the Memphis acquisition.

• Net loss attributable to common stockholders was $15.7 million, or $(0.35) per share.
• Consolidated total revenues increased to $51.9 million.

ADTRAN Holdings, Inc. announced its preliminary unaudited financial results for the third quarter of 2024, featuring sequential revenue growth and margin expansion. The company's revenue reached $227.7 million, surpassing the midpoint of its guidance. Gross and operating margins also improved, with non-GAAP operating margin turning positive. The company anticipates continued revenue growth in Q4 2024.

• Revenue reached $227.7 million, exceeding the midpoint of guidance.
• GAAP gross margin was 37.4%, while non-GAAP gross margin was 42.1%, reflecting sequential increases.

Montrose Environmental Group reported a record third quarter with a 6.4% increase in total revenue, reaching $178.7 million. The company's Consolidated Adjusted EBITDA increased by 21.5% to $28.3 million. However, the company reported a net loss of $10.6 million, or $0.39 net loss per diluted share.

• Highest-ever total revenue of $178.7 million, an increase of 6.4%.
• Net loss of $10.6 million, or $0.39 net loss per diluted share.

Excelerate Energy reported a solid third quarter in 2024, marked by a net income of $45.5 million and an adjusted EBITDA of $92.3 million. The company raised and narrowed its full-year Adjusted EBITDA guidance to a range of $335 million to $345 million. Additionally, the company increased its quarterly cash dividend by 140% from the prior quarter.

• Reported net income of $45.5 million for Q3 2024.
• Reported Adjusted EBITDA of $92.3 million for Q3 2024.

The ODP Corporation reported a decrease in sales by 11% compared to the previous year, with total sales of $1.8 billion. GAAP EPS was $2.04 and adjusted EPS was $0.71. The company is progressing on its B2B pivot, with significant new business wins, and completed the Varis sale subsequent to the quarter end. The company repurchased approximately $295 million of shares year to date.

• Total reported sales were $1.8 billion, down 11% versus the prior year, primarily due to lower sales in the Office Depot and ODP Business Solutions Divisions.
• GAAP operating income was $102 million, and net income from continuing operations was $68 million, or $2.04 per diluted share.

Riley Exploration Permian reported Q3 2024 financial results, including revenues of $102.3 million, net income of $25.7 million, and adjusted EBITDAX of $71.7 million. The company averaged 23.4 MBoe/d of total equivalent production, with oil production of 15.5 MBbls/d. Riley Permian reduced debt by $35 million and generated $37.8 million in free cash flow.

• Averaged 23.4 MBoe/d of total equivalent production with oil production of 15.5 MBbls/d.
• Generated $72.1 million of operating cash flow.

Clean Energy Fuels Corp. reported a revenue increase to $104.9 million, up from $95.6 million in Q3 2023. RNG gallons sold also increased by 5.1% to 59.6 million gallons. However, the company experienced a net loss attributable to Clean Energy of $(18.2) million, or $(0.08) per share.

• Revenue increased to $104.9 million compared to $95.6 million in Q3 2023.
• RNG gallons sold increased 5.1% to 59.6 million gallons.

ZipRecruiter reported Q3 2024 results with revenue of $117.1 million and a net loss of $2.6 million. The company's Board of Directors authorized a $100 million increase to its share repurchase program.

• Quarterly revenue was $117.1 million.
• Quarterly net loss was ($2.6) million, resulting in a net loss margin of (2)%.

Arbutus Biopharma reported a net loss of $19.7 million for the third quarter of 2024, with total revenue of $1.3 million. The company's cash runway extends into the fourth quarter of 2026, and it is advancing the development of imdusiran and AB-101.

• Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024.
• Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy.

Conduent reported its Q3 2024 financial results, with revenue at $807 million and adjusted revenue at $781 million. The company's pre-tax income was $159 million, and the adjusted EBITDA margin was 4.1%. New business signings ACV reached $111 million, and the net ARR activity metric (TTM) was $46 million.

• Revenue was reported at $807 million.
• Adjusted Revenue reached $781 million.

A-Mark Precious Metals reported a 9% increase in revenue to $2.72 billion compared to the same quarter last year, but net income attributable to the company decreased by 52% to $9.0 million. Diluted earnings per share were $0.37, a 52% decrease year-over-year. The company's Board of Directors reaffirmed its quarterly cash dividend policy of $0.20 per share.

• Revenues increased 9% to $2.72 billion compared to the same quarter last year.
• Diluted earnings per share totaled $0.37, a 52% decrease compared to the same quarter last year.

OrthoPediatrics Corp. announced strong third-quarter results with a 37% increase in revenue compared to the same period last year. The company also increased its full-year revenue guidance for 2024, reflecting positive momentum and strategic execution across all business segments.

• Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023
• Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarter

Genco Shipping & Trading Limited reported a net income of $21.5 million for Q3 2024, with basic earnings per share of $0.50. The company declared a dividend of $0.40 per share. They also acquired the Genco Intrepid and enhanced their dividend policy.

• Declared a dividend of $0.40 per share for Q3 2024, representing the 21st consecutive quarterly dividend.
• Acquired the Genco Intrepid, a high specification 2016-built Capesize vessel.

Emergent BioSolutions reported a strong Q3 2024 with a 9% increase in total revenues to $293.8 million and a 144% increase in net income to $114.8 million compared to the prior year. Adjusted EBITDA also saw a significant rise of 432% to $105.3 million. The company has raised its full-year 2024 guidance, reflecting improved financial performance and strategic progress.

• Total revenues for Q3 2024 increased by 9% year-over-year, reaching $293.8 million.
• Net income for Q3 2024 saw a substantial increase of 144% compared to the previous year, amounting to $114.8 million.

American Coastal Insurance Corporation reported a strong third quarter, with increased returns on equity and a combined ratio lower than 60%. Total revenue was $82.1 million, a 56% increase year-over-year.

• Net income for the third quarter of 2024 was $28.1 million, or $0.57 per diluted share, compared to $10.6 million, or $0.24 per diluted share, for the third quarter of 2023.
• Total revenue was $82.1 million, a 56% increase year-over-year.

Astronics Corporation reported a 25% increase in sales to $203.7 million in the third quarter of 2024, the highest quarterly level since Q1 2019. The company's adjusted EBITDA grew by 207% to $27.1 million, with Aerospace segment adjusted operating margin at 14.2%. However, the company experienced a net loss of $11.7 million, which included $7.0 million in refinancing costs, though adjusted net income was $12.2 million.

• Sales increased by $40.8 million to $203.7 million, marking the highest quarterly sales since Q1 2019.
• Aerospace operating income reached $14.3 million, with an adjusted operating income of $25.3 million, representing 14.2% of sales.

Cross Country Healthcare's third quarter results showed stabilization across the core business with momentum in Homecare, Physician, and Education Staffing. Revenue was $315.1 million, a decrease of 29% year-over-year, and net income attributable to common stockholders was $2.6 million.

• Revenue, Adjusted EBITDA, and Adjusted EPS all within guidance ranges
• Physician Staffing and Homecare Staffing experienced sequential and year-over-year revenue growth

FRP Holdings reported an 8% increase in net income and a 39% increase in pro rata NOI compared to the same period last year. The growth in pro rata NOI was driven by increases across all segments, particularly in the Mining and Royalties segment.

• Net income increased by 8% ($1.4 million vs $1.3 million).
• Pro rata NOI increased by 39% ($11.3 million vs $8.1 million).

FARO Technologies reported Q3 2024 revenue of $82.6 million, with a GAAP net loss of $0.3 million, or $(0.02) per share, and non-GAAP EPS of $0.21. The company achieved a gross margin of 55.7% and non-GAAP gross margin of 56.1%.

• Revenue of $82.6 million, at the upper end of guidance range.
• Gross margin of 55.7%; Non-GAAP gross margin 56.1%, above guidance range.

Surmodics reported a 19% year-over-year increase in total revenue for Q4 2024, driven by strong performance in the Medical Device segment. The company's GAAP net loss was $(3.4) million, while adjusted EBITDA reached $4.4 million.

• Total revenue increased by 19% year-over-year to $33.2 million.
• Medical Device revenue grew by 22% to $25.8 million, driven by vascular interventional products and performance coating reagents.

Global Medical REIT reported a decrease in rental revenue to $34.2 million and net income of $1.8 million, or $0.03 per diluted share, for the third quarter of 2024. The company completed acquisitions of medical properties and sold two assets, while maintaining a portfolio occupancy of 96.1%.

• Completed the acquisition of five properties in the 15-property portfolio for $30.8 million with annualized base rent of $2.5 million.
• Sold two medical facilities for gross proceeds of $12.1 million, resulting in a gain of $1.8 million.

Mativ reported a slight increase in sales and a significant improvement in GAAP loss for Q3 2024. Sales increased by 0.1% year over year, and GAAP loss improved by $443.5 million compared to the prior year. Adjusted EBITDA was up 10% versus the prior year.

• Sales increased 0.1% year over year, and 1.4% on an organic basis.
• GAAP loss improved by $443.5 million compared to the prior year, with GAAP EPS at $(0.38).

Dine Brands Global, Inc. reported a decrease in total revenues for Q3 2024, primarily due to negative comparable same-restaurant sales growth at Applebee’s and IHOP. Despite the revenue decline, the company's adjusted EBITDA increased slightly, and GAAP net income available to common stockholders also increased.

• Total revenues for the third quarter of 2024 were $195.0 million, compared to $202.6 million for the third quarter of 2023.
• Applebee’s domestic comparable same-restaurant sales decreased by 5.9% for the third quarter of 2024.

Service Properties Trust announced its financial results for the quarter ended September 30, 2024.

• Financial results for Q3 2024 were released.
• A conference call to discuss Q3 results will be held on November 7, 2024.

Keros Therapeutics reported a net loss of $53.0 million for the third quarter of 2024, driven by increased research and development expenses. The company's cash and cash equivalents as of September 30, 2024, were $530.7 million, which is expected to fund operations into the third quarter of 2027.

• Completed enrollment ahead of schedule in Phase 2 TROPOS trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension.
• Yung H. Chyung, M.D., was appointed as Chief Medical Officer, effective November 1, 2024.

Franklin Covey reported strong Q4 results, with revenue up 8% to $84.1 million and net income up 76% to $12.0 million. The company's performance reflects the successful transition to a technology-enabled content and services subscription business model.

• Consolidated fourth-quarter revenue increased 8% to $84.1 million.
• Fourth-quarter net income increased 76% to $12.0 million.

SandRidge Energy reported a net income of $25.5 million, or $0.69 per basic share, for the third quarter of 2024. The company's production averaged ~19 MBoe/d in September, reflecting a 27% increase versus 2Q24, and adjusted EBITDA was $17.7 million for the same period. The company closed on its acquisition of certain producing oil and natural gas properties in the Cherokee play of the Western Anadarko Basin.

• Declared a $0.11 per share cash dividend payable on November 29, 2024.
• Closed on the acquisition of certain producing oil and natural gas properties in the Cherokee play of the Western Anadarko Basin.

UroGen Pharma reported JELMYTO net product revenues of $25.2 million for Q3 2024, compared to $20.9 million for Q3 2023. The FDA accepted the New Drug Application for UGN-102, with a PDUFA target action date set for June 13, 2025. As of September 30, 2024, the company had $254.2 million in cash, cash equivalents, and marketable securities.

• FDA accepted the New Drug Application for UGN-102 with a PDUFA target action date of June 13, 2025.
• JELMYTO achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in Q3 2023.

Bowman Consulting Group Ltd. reported strong financial results for Q3 2024, exceeding $100 million in net revenue for the first time. The company focused on aligning labor with revenue, capitalizing on economies of scale, and increasing free cash flow generation.

• Gross contract revenue increased by 21% to $113.9 million.
• Net service billing increased by 23% to $101.4 million.

Personalis reported a 41% year-over-year increase in revenue, driven by a 96% increase in biopharma revenue. The company raised its 2024 revenue guidance and secured significant financing, extending its cash runway into the first half of 2027.

• Total company revenue increased by 41% year-over-year to $25.7 million.
• Biopharma revenue grew by 96% year-over-year to $15.7 million.

Ur-Energy Inc. reported increased production at Lost Creek, with 100,000 pounds U3O8 sold at an average price of $61.65 per pound, resulting in $6.2 million in proceeds. The company anticipates revenues of $33.1 million from 2024 U3O8 sales and expects to increase company wide production capacity to 2.2M pounds per year in early 2026. As of September 30, 2024, the company had cash resources of $129.4 million.

• Production at Lost Creek continued to increase quarter over quarter.
• Development and construction programs at Shirley Basin continue to advance.

Xperi Inc. reported third quarter results with a focus on entertainment-based solutions, growing its media platform and licensing businesses. The TiVo OS Smart TV footprint is approaching one million units, and the company is on track to achieve its year-end target of two million smart TVs. The Perceive transaction closed for gross proceeds of $80 million in cash.

• TiVo OS Smart TV footprint is approaching one million activated units and tracking toward a year-end goal of two million.
• DTS AutoStage video design won with a Japanese automotive OEM.

Matrix Service Company reported a revenue of $165.6 million and a net loss per share of $(0.33) for the first quarter of fiscal year 2025. The company is maintaining its full-year fiscal 2025 revenue guidance of $900 to $950 million, supported by continued demand strength and a total backlog of $1.4 billion.

• Reiterated full-year fiscal 2025 revenue guidance of $900 to $950 million.
• Total backlog reached $1.4 billion.

Gladstone Land reported net income of $6,000 for the quarter, a significant decrease from the $3.1 million in the prior-year quarter. AFFO was approximately $4.5 million, or $0.13 per share, compared to $5.4 million, or $0.15 per share, in the prior-year quarter. The company faced challenges with certain vacant, direct-operated, and non-accrual properties, as well as changes in lease structures on permanent crop farms.

• Net income decreased to $6,000 from $3.1 million year-over-year.
• AFFO decreased to $4.5 million, or $0.13 per share, from $5.4 million, or $0.15 per share, year-over-year.

MaxCyte reported a 2% increase in total revenue, reaching $8.2 million in Q3 2024. Core business revenue grew by 23% to $8.1 million, driven by a 39% increase in cell therapy revenue. The company signed six new SPL clients year-to-date, bringing the total to 29. MaxCyte is also evaluating cost reduction opportunities, including a potential cancellation of its AIM listing.

• Total revenue increased by 2% to $8.2 million in Q3 2024.
• Core business revenue increased by 23% to $8.1 million in Q3 2024.

Genie Energy reported a decrease in revenue and profitability for the third quarter of 2024. Revenue decreased by 10.5% to $111.9 million, and net income attributable to Genie common stockholders decreased to $10.2 million, or $0.38 per diluted share. The company is on track to deliver the high end of its full year Adjusted EBITDA guidance of $40 to $50 million.

• Revenue decreased 10.5% to $111.9 million.
• Gross profit decreased 7.7% to $37.9 million, with gross margin increasing to 33.9%.

REGENXBIO reported a net loss of $59.6 million for the third quarter of 2024, with revenues of $24.2 million. The company's cash, cash equivalents, and marketable securities totaled $278.6 million as of September 30, 2024, expected to fund operations into 2026. Key advancements include progress in the RGX-202 and ABBV-RGX-314 trials, and initiation of the BLA submission for RGX-121.

• Advanced Phase I/II AFFINITY DUCHENNE trial of RGX-202 for Duchenne Muscular Dystrophy, with pivotal trial initiation and first functional data expected this month.
• Initiated BLA submission for RGX-121, expected to be completed in Q1 2025.

Regional Management Corp. reported strong Q3 2024 results with record revenue of $146.3 million and net income of $7.7 million, despite a $4.3 million impact from hurricane activity. The company's portfolio grew by $46 million sequentially, and credit performance improved. The operating expense ratio also improved by 50 basis points year-over-year.

• Net income reached $7.7 million, with diluted EPS of $0.76, including a $4.3 million impact from hurricane events.
• Record revenue was driven by $46 million of sequential portfolio growth, representing an annualized growth rate of 10%.

NewtekOne reported a net income of $11.9 million and EPS of $0.45 for the third quarter of 2024. The results were driven by growth in deposits, loans, and the payments segment.

• Net income was $11.9 million, with EPS at $0.45 per basic and diluted common share.
• Net interest income increased by 35.8% year-over-year to $11.0 million.

Park-Ohio Holdings Corp. announced its Q3 2024 results with net sales of $417.6 million, a gross margin of 17.3%, and adjusted EPS of $1.07. The company saw improved profitability driven by the Supply Technologies segment and higher sales in the Engineered Products segment. They anticipate modest growth in Q4 and into 2025, along with continued debt reduction.

• Net sales were $417.6 million compared to $418.8 million in Q3 2023.
• Gross margin improved to 17.3%, up 60 basis points year-over-year.

Health Catalyst reported strong financial results for Q3 2024, with total revenue of $76.4 million and Adjusted EBITDA of $7.3 million, both exceeding the midpoint of their quarterly guidance. They are raising their Adjusted EBITDA guidance by $1 million for 2024.

• Total revenue reached $76.4 million.
• Adjusted EBITDA was $7.3 million.

Kaltura reported a 2% increase in revenue, record subscription revenue and ARR, a record high in cash flow, and positive Adjusted EBITDA for the fifth consecutive quarter. The company also increased its revenue and Adjusted EBITDA guidance for the full year and expects to post positive cash flow from operations in the fourth quarter and for the full year.

• Delivered record subscription revenue and ARR.
• Cash flow was at a record high.

Bridge Investment Group reported a net income of $10.6 million for Q3 2024. The company declared a quarterly dividend of $0.10 per share of Class A common stock. Bridge's operations and financial results remained resilient with optimism about the business outlook.

• Net Income was $10.6 million.
• Net income attributable to Bridge per share of Class A common stock was $0.11 basic and $0.04 diluted.

Traeger reported a 3.7% increase in total revenue to $122.1 million, driven by a 32.5% increase in grill revenue. Gross margin improved to 42.3%, leading to an adjusted EBITDA of $12.3 million. The company raised its full-year revenue, gross margin, and adjusted EBITDA guidance.

• Total revenues increased by 3.7% to $122.1 million.
• Grill revenues increased by 32.5% to $74.9 million.

MasterCraft Boat Holdings reported net sales of $65.4 million, a decrease of 30.7% compared to the prior-year period. Income from continuing operations was $1.0 million, or $0.06 per diluted share, while adjusted net income was $1.9 million, or $0.12 per diluted share.

• Net sales for the first quarter were $65.4 million, down 30.7% from the prior-year period.
• Income from continuing operations was $1.0 million, or $0.06 per diluted share.

OraSure Technologies reported Q3 2024 revenue of $39.9 million, a 55% decrease compared to Q3 2023. Core revenues decreased by 1% year-over-year, while COVID-19 revenues declined significantly. The company is exiting its Risk Assessment testing business to focus on Diagnostics and Sample Management.

• Q3 2024 revenue was $39.9 million, a 55% decrease year-over-year.
• Core revenues decreased 1% year-over-year, with Diagnostics up 13% and Molecular Sample Management down 16%.

eHealth, Inc. announced its Q3 2024 financial results, achieving revenue and profitability targets while experiencing growth in Medicare application volume. Total revenue decreased by 10% year-over-year to $58.4 million, while Medicare submissions grew by 22%. The company reiterated its full-year 2024 guidance.

• Medicare submissions across core agency and Amplify platforms grew 22% year-over-year.
• Total Medicare approved members increased 6% year-over-year.

CS Disco reported a 4% increase in total revenue to $36.3 million for Q3 2024. The company's GAAP net loss was $9.2 million, compared to $1.0 million in the third quarter of 2023.

• Total revenue was $36.3 million, up 4% compared to the third quarter of 2023.
• Software revenue was $30.2 million, up 6% compared to the third quarter of 2023.

SmartRent reported a 30% decrease in total revenue year-over-year, totaling $40.5 million, while SaaS revenue increased by 23% to $13.3 million. The company's net loss increased to $(9.9) million, but adjusted EBITDA improved by 24% to $(3.8) million. SmartRent repurchased 9.8 million shares at a cost of $17.1 million and ended the quarter with $163.7 million in cash and cash equivalents.

• Total revenue decreased by 30% year-over-year to $40.5 million.
• SaaS revenue increased by 23% year-over-year to $13.3 million.

Ring Energy reported a strong third quarter in 2024, marked by record sales of 20,108 Boe/d, a strategic divestiture of non-core assets for $5.5 million, and a $15 million reduction in debt. The company's performance reflects successful execution of its drilling and completion program and a focus on reducing operating costs.

• Achieved record sales of 20,108 Boe/d, exceeding the high end of guidance.
• Reported net income of $33.9 million, or $0.17 per diluted share.

Beyond Meat reported a 7.6% increase in net revenues to $81.0 million and a gross profit of $14.3 million, a significant improvement from the previous year. The company also narrowed its operating loss and net loss, driven by increased gross profit and reduced operating expenses. The company expects to increase cash reserves by year-end and pursue further balance sheet restructuring in 2025.

• Net revenues increased by 7.6% year-over-year to $81.0 million.
• Gross profit was $14.3 million, with a gross margin of 17.7%.

Aclaris Therapeutics reported a decrease in revenue for the third quarter of 2024, primarily driven by lower milestone payments compared to the previous year. The company highlighted the dosing of the first patient in the Phase 2a trial of ATI-2138 for atopic dermatitis and anticipates top-line data in the first half of 2025.

• First patient dosed in the Phase 2a trial of ATI-2138 for atopic dermatitis.
• Aclaris is progressing a second-generation ITK selective inhibitor to development candidate selection for autoimmune indications.

Vanda Pharmaceuticals reported Q3 2024 financial results, with revenues of $47.7 million, a 23% increase compared to Q3 2023. The company launched Fanapt® in bipolar I disorder and PONVORY® for multiple sclerosis. A net loss of $5.3 million was reported, and financial guidance for the full year 2024 was revised, raising the midpoint of revenue and cash ranges.

• Total revenues for Q3 2024 were $47.7 million, a 23% increase compared to Q3 2023.
• Fanapt® launch in bipolar I disorder led to a new patient start increase of over 90% compared to Q3 2023.

iRobot reported Q3 2024 financial results, showing progress in its turnaround strategy with expanded non-GAAP gross margin and improved operating cash use. However, overall results missed expectations due to market headwinds, leading to a revision of the full-year 2024 outlook. The company is on track to exceed operating expense targets while continuing to invest in growth areas.

• Non-GAAP gross margin increased by 590 basis points year-over-year due to restructuring and iRobot Elevate initiatives.
• Cash and cash equivalents totaled $99.4 million as of September 28, 2024.

Digital Turbine reported a decrease in revenue year-over-year but an increase sequentially for the second quarter of fiscal year 2025. The company reported a GAAP net loss of $25.0 million, or ($0.24) per share, and a non-GAAP adjusted net income of $5.0 million, or $0.05 per share. The company initiated a transformation program designed to drive greater efficiency and enhance cash flow generation.

• Second quarter revenue totaled $118.7 million, a 17% decrease year-over-year.
• GAAP net loss was $25.0 million, or ($0.24) per share.

Accuray reported a slight decrease in total net revenue for Q1 2025 compared to the prior year, but saw strength in the China region and growth in its service business. The company raised its fiscal year 2025 revenue and adjusted EBITDA guidance.

• Total net revenue was $101.5 million, compared to $103.9 million in the prior year.
• Product revenue was $48.4 million, compared to $53.4 million in the prior year.

Kingsway Financial Services reported a 9.5% increase in consolidated revenue, reaching $27.1 million for Q3 2024. However, the company experienced a net loss of $2.3 million. The company completed the acquisition of Image Solutions and saw revenue increases in both its Extended Warranty and KSX segments.

• Consolidated revenue increased by 9.5% to $27.1 million.
• Extended Warranty revenue increased by 3.4% to $17.8 million.

Amplify Energy Corp. reported a net income of $22.7 million and Adjusted EBITDA of $25.5 million for Q3 2024. The company focused on its Beta field development program, with the C59 well exceeding production expectations. While evaluating monetization of Wyoming assets, Amplify decided to retain them, prioritizing shareholder value in the current commodity price environment.

• Achieved average total production of 19.0 MBoepd.
• Generated net income of $22.7 million and Adjusted EBITDA of $25.5 million.

Entravision Communications Corporation reported a 25% increase in net revenue from continuing operations for Q3 2024 compared to the same quarter in 2023, driven primarily by growth in political advertising revenue and Smadex. The company's Board of Directors approved a quarterly cash dividend of $0.05 per share.

• Realigned operating segments into Media and Advertising Technology & Services.
• Net revenue from continuing operations increased by 25% compared to Q3 2023.

Sera Prognostics reported third quarter 2024 revenue of $29,000, a decrease from $42,000 in the same period of 2023. The net loss for the quarter was $7.9 million, compared to $7.2 million for the prior-year period.

• Data analysis for full PRIME study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025.
• Awareness campaign activated with TV programs by Viewpoint with Dennis Quaid and Empowered with Meg Ryan.

Cardlytics reported a revenue of $67.1 million, a 15% decrease year-over-year, and a net loss of $145.2 million, or $2.90 per diluted share, compared to a net loss of $24.0 million, or $0.63 per diluted share in the third quarter of 2023. The company's MAUs increased by 2% year-over-year to 166.4 million, while ARPU decreased to $0.40 from $0.49 in the third quarter of 2023.

• Revenue was $67.1 million, a decrease of 15% year-over-year, or 13% excluding Entertainment.
• Billings were $112.0 million, a decrease of 4% year-over-year, or 2% excluding Entertainment.

Myomo reported a record third quarter with significant revenue growth, driven by increased product revenue and higher average selling prices. The company saw growth in MyoPro units, backlog, and additions to the patient pipeline. Gross margin improved, and the company is focused on expanding its sales channels and achieving operating cash flow breakeven.

• Product and total revenue reached a record $9.2 million, up 83% and 81%, respectively.
• Orders and insurance authorizations were received for a record 225 MyoPro units, up 44%.

TTEC reported a decrease in revenue and a net loss for the third quarter of 2024, while focusing on diversification, AI-enabled CX solutions, and operational agility to strengthen financial performance amidst industry and macroeconomic headwinds.

• Third Quarter 2024 Revenue was $529.4 Million, down 12.2 Percent
• Operating Income of $12.9 Million or 2.4 Percent of Revenue

Alector reported a net loss of $42.2 million, or $0.43 per share, for the quarter ended September 30, 2024. As of September 30, 2024, Alector’s cash, cash equivalents, and investments totaled $457.2 million, which is expected to fund operations through 2026.

• Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024
• Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)

Braemar Hotels & Resorts reported a net loss attributable to common stockholders of $(1.4) million, or $(0.02) per diluted share, for the third quarter ended September 30, 2024. Comparable RevPAR decreased 1.6% over the prior year quarter to $261. The company closed on the sale of the Hilton La Jolla Torrey Pines for $165 million and a refinancing involving five hotels for $407 million.

• Comparable RevPAR decreased 1.6% year-over-year to $261.
• Net loss attributable to common stockholders was $(1.4) million, or $(0.02) per diluted share.

Full House Resorts announced its Q3 2024 results, showing a revenue increase to $75.7 million compared to $71.5 million in the prior year. However, the company reported a net loss of $8.5 million, or $(0.24) per diluted common share, compared to a net income of $4.6 million, or $0.13 per diluted common share, in the prior-year period. Adjusted EBITDA was $11.7 million, down from $20.6 million in the prior year.

• Revenues increased significantly compared to the third quarter of 2023.
• Chamonix Casino Hotel celebrated its official grand opening.

Granite Point Mortgage Trust Inc. reported a GAAP Net Loss of $(34.6) million, or $(0.69) per basic share, and a Distributable Loss of $(38.0) million, or $(0.75) per basic share for the quarter ending September 30, 2024. The company resolved multiple nonaccrual loans and continued share buybacks.

• GAAP Net (Loss) of $(34.6) million, or $(0.69) per basic share, inclusive of a $(27.9) million provision for credit losses.
• Distributable (Loss) of $(38.0) million, or $(0.75) per basic share, inclusive of loan write-offs of $(44.6) million and recoveries of $8.8 million.

Virgin Galactic reported a revenue of $0.4 million and a net loss of $75 million in Q3 2024. The company's cash position remains strong with $744 million in cash, cash equivalents, and marketable securities. The production schedule for Delta Class spaceships remains on track for commercial service in 2026.

• Cash position remains strong, with cash, cash equivalents and marketable securities of $744 million as of September 30, 2024.
• Revenue of $0.4 million, compared to $1.7 million in the third quarter of 2023, with the decrease driven by the pause in commercial spaceflights to focus efforts on the production of the Delta Class spaceships.

Trinseo's Q3 2024 results showed a net loss of $87 million, but an improved adjusted EBITDA of $66 million compared to the previous year. The company's net sales reached $868 million, slightly below the prior year. Restructuring initiatives and moderation of European input costs contributed to profitability improvements.

• Net loss was $87 million, including $26 million in pre-tax restructuring charges, with an EPS of negative $2.47.
• Adjusted EBITDA reached $66 million, $25 million higher than the previous year.

Seer, Inc. reported revenue of $4.0 million for the third quarter of 2024, a 3% decrease compared to the prior year. The company's net loss was $21.3 million. They ended the quarter with approximately $312 million in cash, cash equivalents and investments.

• Revenue for the third quarter of 2024 reached $4.0 million.
• A co-marketing and sales agreement was established with Thermo Fisher Scientific.

Forge Global Holdings reported a 4% year-over-year increase in total revenue, less transaction-based expenses, reaching $19.1 million. The company's trading volume increased by 44% to $338.1 million. Forge also launched Forge Price, a new pricing transparency initiative.

• Total revenue, less transaction-based expenses, increased by 4% year-over-year to $19.1 million.
• Marketplace revenues, less transaction-based expenses, increased by 21% year-over-year.

Coherus BioSciences reported net revenue of $70.8 million for Q3 2024, driven by a 30% increase in UDENYCA net revenue quarter-over-quarter and LOQTORZI revenue increased 50% quarter-over-quarter. The company's sharpened focus on oncology is delivering results, with Q3 2024 revenues comparable to Q3 2023, despite divestitures, and with higher gross profit, lower operating expenses and lower interest expense. The company is advancing its immuno-oncology pipeline to proof-of-concept studies in combination with toripalimab.

• Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter.
• UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization.

Caribou Biosciences reported a net loss of $34.7 million for the third quarter of 2024, with licensing and collaboration revenue of $2.0 million. The company's cash, cash equivalents, and marketable securities totaled $281.0 million as of September 30, 2024, expected to fund operations into H2 2026.

• Advanced four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple clinical data reports planned for 2025.
• Enrolled patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025.

Alto Ingredients reported improved production capabilities at its Pekin campus, leading to increased specialty alcohol sales and a 40% year-over-year increase in consolidated gross profit. The company also entered into a CO2 Transportation and Sequestration Agreement with Vault 44.01, marking a step toward sustainability.

• Increased production capabilities and uptime at the Pekin campus compared to the prior year quarter.
• Specialty alcohol sales increased by 4 million gallons compared to last year.

Red Robin's third quarter results were in line with expectations, with comparable restaurant revenue exceeding the industry average. Guest satisfaction scores improved to levels not seen since 2016, and the relaunched loyalty program showed potential. The company is focused on executing its strategic plan to drive long-term growth.

• Total revenues decreased by $2.9 million to $274.6 million.
• Comparable restaurant revenue increased by 0.6%.

PetMed Express reported net sales of $59.6 million and a net income of $2.3 million, or $0.11 per diluted share, for the second quarter of fiscal year 2025. The company saw a gross margin of 29.1%, an increase of 0.8% compared to the prior year period. Adjusted EBITDA improved sequentially to $2.1 million.

• Net sales reached $59.6 million.
• Gross margin increased to 29.1%, up 0.8% year-over-year.

Tenaya Therapeutics reported positive safety update and DSMB clearance to dose escalate to Cohort 2 in the MyPEAK-1 study. They remain on track to report early clinical data from the first three patients from Cohort 1 of this study in December. As of September 30, 2024, cash, cash equivalents and investments in marketable securities were $79.5 million.

• Completed dosing of the first three patients at the 3E13 vg/kg dose (Cohort 1) in MyPEAK-1 clinical trial with no unexpected events or toxicities associated with study drug observed.
• Implemented changes to the MyPEAK-1 protocol intended to support future development, including adding a baseline biopsy; expanding trial participant eligibility to include obstructive HCM patients and patients without implantable cardioverter defibrillators (ICDs).

DBV Technologies reported its Q3 2024 financial results, revealing a cash balance of $46.4 million. The company's operating income was $1.1 million. The company experienced a net loss of $30.4 million, with a basic/diluted net loss per share of $(0.32).

• Cash and cash equivalents amounted to $46.4 million as of September 30, 2024.
• Operating income for the quarter was $1.1 million.

WW International reported a decrease in revenues and subscribers for Q3 2024, with revenues at $192.9 million and a decline in total subscribers to 3.7 million. However, the company saw growth in clinical subscribers and an improvement in gross margin. The company is reiterating its full year fiscal 2024 guidance.

• End of Period Subscribers decreased to 3.7 million.
• Revenues reached $192.9 million.

Adicet Bio reported a net loss of $30.5 million for the third quarter of 2024, with cash, cash equivalents, and short-term investments totaling $202.1 million as of September 30, 2024. The company is advancing its clinical pipeline, including ADI-001 for autoimmune diseases and ADI-270 for solid tumors.

• Expanded ADI-001 Phase 1 clinical trial to include six autoimmune disease indications.
• Preliminary clinical data in lupus nephritis (LN) anticipated in 1H25.

Aadi Bioscience reported FYARRO sales of $7.2 million for Q3 2024, reflecting a 21% year-over-year increase. The company is actively engaged in a comprehensive strategic review to maximize shareholder value and expects current resources to fund operations into at least 2H 2026.

• FYARRO net product sales were $7.2 million, a 17% increase from Q2 2024 and a 21% increase year-over-year.
• Aadi completed the wind-down of the PRECISION1 trial, with a report expected in 2025.

Modivcare's Q3 2024 results showed a 2.2% increase in service revenue to $702.0 million. However, the company reported a net loss of $26.6 million, or negative $1.87 per diluted common share, due to increased interest expense and a loss on debt extinguishment. Adjusted EBITDA was $43.2 million, with adjusted EPS at $0.45. The company is focused on cost savings and growth in its personal care services and remote patient monitoring segments and has affirmed its 2024 guidance.

• Service revenue increased by 2.2% year-over-year to $702.0 million.
• Net loss was $26.6 million, or negative $1.87 per diluted common share.

Prelude Therapeutics reported its third quarter financial results, highlighting the clinical proof of concept for PRT3789, its IV SMARCA2 degrader, and the initiation of a Phase 1 trial for PRT7732, its oral SMARCA2 degrader. The company's cash runway extends into 2026, with $153.6 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

• Demonstrated clinical proof of concept with PRT3789, its IV SMARCA2 degrader.
• Initiated a Phase 1 trial for PRT7732, its oral SMARCA2 degrader.

Generation Bio reported a net loss of $15.3 million for Q3 2024, an improvement compared to the $28.3 million net loss in Q3 2023. The company's cash, cash equivalents, and marketable securities totaled $199.8 million as of September 30, 2024, which is expected to fund operations into the second half of 2027.

• Cash balance of $199.8 million expected to fund operations into 2H 2027.
• R&D expenses decreased to $15.1 million compared to $21.9 million in Q3 2023.

Regis Corporation reported a decrease in consolidated revenue to $46.1 million compared to $53.4 million in the prior year, driven by lower store count and same-store sales. The company experienced a net loss of $0.9 million compared to a net income of $1.2 million in the prior year, with diluted EPS of ($0.36). Adjusted net income was $2.6 million, and adjusted EBITDA was $7.6 million.

• Consolidated revenue decreased to $46.1 million from $53.4 million due to fewer stores and lower same-store sales.
• Same-store-sales decreased 1.1% compared to the prior year.

Allbirds' Q3 2024 net revenue decreased by 24.9% to $43.0 million compared to the previous year, but was within the company's guidance range. Gross margin improved to 44.4%. The company is updating its full year 2024 revenue guidance and narrowing its Adjusted EBITDA guidance range.

• Net revenue decreased 24.9% to $43.0 million year-over-year, within guidance.
• Gross margin improved approximately 90 basis points to 44.4% year-over-year.

Outset Medical reported a slight decrease in revenue compared to Q3 2023, but experienced sequential growth from Q2 2024. The company saw improvements in gross margin and achieved record recurring revenue. They also increased revenue guidance for the full year.

• Revenue for the third quarter was $28.7 million, a 5% increase compared to the second quarter and a 6% decrease from the third quarter of 2023.
• Product revenue was $20.3 million, a 6% increase from the second quarter and a 14% decrease from the third quarter of 2023.

SLR Investment Corp. reported net investment income of $0.45 per share for the third quarter of 2024. The company's NAV remained stable at $18.20 per share. The board declared a quarterly distribution of $0.41 per share.

• Net investment income was $0.45 per share.
• A quarterly distribution of $0.41 per share was declared.

BlackRock TCP Capital Corp. reported a solid adjusted net investment income of $30.8 million, or $0.36 per share, for the third quarter, resulting in an adjusted annualized NII return on average equity of 14%. The board approved a special dividend of $0.10 per share and re-approved the authorization to repurchase up to $50.0 million of common stock.

• Net investment income for the quarter ended September 30, 2024 was $33.9 million, or $0.40 per share on a diluted basis.
• Adjusted net investment income for the quarter ended September 30, 2024 was $30.8 million, or $0.36 per share on a diluted basis.

Barings BDC reported a net investment income well above the dividend, strong credit metrics, and NAV that is above where it was at the end of last year. The company made 11 new investments totaling $88.4 million and investments in existing portfolio companies totaling $36.6 million.

• Net investment income was $30.2 million, or $0.29 per share.
• Net increase in net assets resulting from operations was $22.0 million, or $0.21 per share.